staurosporine has been researched along with midostaurin in 438 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.23) | 18.7374 |
| 1990's | 69 (15.75) | 18.2507 |
| 2000's | 102 (23.29) | 29.6817 |
| 2010's | 185 (42.24) | 24.3611 |
| 2020's | 81 (18.49) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K | 1 |
| Augustin, M; Davies, SP; Gao, Y; Harvey, KJ; Kovelman, R; Patel, UA; Woodward, A | 1 |
| Dewhurst, S; Gelbard, HA; Goodfellow, VS; Loweth, CJ; Marker, DF; Nguyen, T; Polesskaya, O; Pollack, S; Ravula, SB; Sheppard, D; Todd, DE; Wiemann, T; Xu, Y | 1 |
| Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S | 1 |
| Huggler, E; Krause, KH; Lew, DP; Monod, A; van Delden, C | 1 |
| Andrejauskas-Buchdunger, E; Regenass, U | 1 |
| Baskin, L; Brandt-Rauf, PW; Chung, DL; Dykes, DC; Friedman, F; Joran, A; Murphy, RB; Robinson, R; Ronai, Z; Weinstein, IB | 1 |
| Brandt-Rauf, PW; Chung, DL; Murphy, RB; Nishimura, S; Pincus, MR; Weinstein, IB; Yamaizumi, Z | 1 |
| Lane, HA; Susa, M; Thomas, G; Vulević, D | 1 |
| Barr, M; Borner, C; Fabbro, D; Guadagno, SN; Hsiao, WW; Weinstein, IB | 1 |
| Fandrey, J; Huwiler, A; Jelkmann, W; Pfeilschifter, J | 1 |
| Keller, H; Niggli, V | 2 |
| Alteri, E; Caravatti, G; Fabbro, D; Matter, A; Meyer, T; Müller, M; Regenass, U; Rösel, J | 1 |
| Bennett, JP; Hammer, B; Parker, WD | 1 |
| Hahn, S; Moroni, C | 1 |
| Budworth, J; Gescher, A | 1 |
| Arbour, N; Houde, M; Mandeville, R; Masure, S; Opdenakker, G; Oth, D; Rochefort, D; Tremblay, P | 1 |
| Comstock, L; Ding, X; Donelli, G; Fasano, A; Fiorentini, C; Goldblum, SE; Guandalini, S; Kaper, JB; Margaretten, K; Uzzau, S | 1 |
| Chorváth, B; Hunáková, L; Sedlák, J; Sulíková, M | 2 |
| Beijnen, JH; Boven, E; de Clippeleir, JJ; Graf, P; Hillebrand, MJ; Schwertz, S; ten Bokkel Huinink, WW; van Gijn, R; van Tellingen, O; Vermorken, JB | 1 |
| Amon, U; Subramanian, N; von Stebut, E; Wolff, HH | 1 |
| Budworth, J; Courage, C; Gescher, A | 1 |
| Agell, N; Bachs, O; Bosch, M; López-Girona, A | 1 |
| Henderson, LK; Matthews, N; Nemec, M; Southern, C; Thorp, KM; Wilkinson, PC | 1 |
| Chorvath, B; Duraj, J; Hunakova, L; Novotny, L; Sedlak, J | 1 |
| Dooley, NP; Noble, PG; Yong, VW | 1 |
| Grunicke, H; Hilbe, W; Hofer, S; Hofmann, J; Regenass, U; Thaler, J; Utz, I | 1 |
| Keller, HU; Niggli, V | 1 |
| Chorváth, B; Novotný, L; Sedlák, J | 1 |
| Fabbro, D; Hynes, NE; Jaken, S; Marte, BM; Meyer, T; Stabel, S; Standke, GJ | 1 |
| Alkan, SS; Erb, P; Grogg, D; Rutschmann, S | 1 |
| Capponi, AM; Church, DJ; Kem, DC; Lang, U; Meda, P; Vallotton, MB; Van der Bent, V | 1 |
| Burkhard, C; Finci-Cerkez, V; Meda, P; Rochat, T | 1 |
| Huwiler, A; Pfeilschifter, J | 1 |
| Blom, M; Koenderman, L; Kok, PT; Lammers, JW; Raaijmakers, JA; van der Bruggen, T; Verhoeven, AJ | 1 |
| Raffaniello, RD; Raufman, JP | 1 |
| Kessels, GC; Krause, KH; Verhoeven, AJ | 1 |
| Chorváth, B; Hunáková, L; Klobusická, M; Sedlák, J; Sulíková, M | 1 |
| Houde, M; Mandeville, R; Masure, S; Opdenakker, G; Oth, D; Tremblay, P | 1 |
| Budworth, J; Davies, R; Ferry, DR; Gant, TW; Gescher, A; Malkhandi, J | 1 |
| De Mazancourt, P; Denis-Henriot, D; Giudicelli, Y; Goldsmith, PK; Lacasa, D | 1 |
| Cherington, V; Corbley, MJ; Lydon, NB; Roberts, TM; Traxler, PM | 1 |
| Ikegami, Y; Nakao, K; Yano, S | 2 |
| Brunelleschi, S; Fantozzi, R; Guidotto, S; Tonso, E; Viano, I | 1 |
| Beijnen, JH; Boven, E; Havik, E; ten Bokkel Huinink, WW; van Gijn, R; van Tellingen, O; Vermorken, JB | 1 |
| Beltran, P; Fan, D; Fidler, IJ; Killion, JJ; O'Brian, CA; Wilson, MR; Yoon, SS | 1 |
| Bunn, SJ; Cheah, TB; Loneragan, K; Marley, PD | 1 |
| Davis, FB; Davis, PJ; Lin, HY; Thacorf, HR | 1 |
| Guignard, F; Markert, M; Mauel, J | 1 |
| Fujita, F; Fujita, M; Ikegami, Y; Isowa, K; Murata, N; Nakao, K; Sakamoto, Y; Yano, S | 1 |
| Baltuch, GH; Yong, VW | 1 |
| Chorváth, B; Duraj, J; Hunáková, L; Sedlák, J; Suliková, M | 1 |
| Beltran, PJ; Fan, D; Fidler, IJ; O'Brian, CA | 1 |
| Goodyer, CG; Oh, LY; Olivier, A; Yong, VW | 1 |
| Courage, C; Gescher, A; Hubbard, A; Jones, T | 1 |
| Houghton, PJ; Luo, W; Sharif, M; Sharif, TR | 1 |
| Cole, T; Liedtke, CM | 1 |
| Church, DJ; Lang, U; Morabito, D; Rebsamen, MC; Vallotton, MB | 1 |
| Bradder, SM; Courage, C; Gescher, A; Jones, T; Schultze-Mosgau, MH | 1 |
| Ehrat, M; Hilfiker, R; Kresbach, GM; Langwost, B; Leuenberger, H; Madörin, M; van Hoogevest, P | 1 |
| Echevaria-Vázquez, D; Fagard, R; Lijnen, P; Petrov, V | 1 |
| Grunicke, H; Hilbe, W; Hofmann, J; Ludescher, C; Regenass, U; Rybczynska, M; Spitaler, M; Utz, I | 1 |
| Gescher, A | 2 |
| Begemann, M; Bruce, JN; Choi, YA; Christiansen, KM; Duigou, G; Fabbro, D; Ghosh, S; Heitjan, DF; Kashimawo, SA; Kim, S; Lampen, NM; Mueller, M; Schieren, I; Schiff, PB; Weinstein, IB | 1 |
| Grosman, N | 1 |
| Sharif, M; Sharif, TR | 1 |
| Akinaga, S; Akiyama, T; Okabe, M; Shimizu, M; Tamaoki, T | 1 |
| Campochiaro, PA; Fabbro, D; Hofmann, F; Kwak, N; Okamoto, N; Ozaki, H; Seo, MS; Wood, JM; Yamada, E; Yamada, H | 1 |
| Balkwill, F; Braybrook, J; Caponigro, F; Dobbs, N; Fabbro, D; Ganesan, T; Harris, A; Hutchison, C; Man, A; McDonald, A; Propper, D; Talbot, D; Thavasu, P; Twelves, C | 1 |
| Beijnen, JH; Bult, A; Haverkate, E; Kettenes-van den Bosch, JJ; van Gijn, R; van Tellingen, O | 1 |
| Acevedo-Duncan, M; Chalfant, CE; Cooper, DR; Goodnight, J; Illingworth, P; Mischak, H; Patel, N; Watson, JE | 1 |
| Förstermann, U; Li, H | 1 |
| Bodis, S; Campochiaro, P; Csermak, K; Fabbro, D; Man, A; Meyer, T; O'Reilly, T; Pruschy, M; Ruetz, S; Wood, J | 1 |
| DiGennaro, JA; Larsen, EC; Lennartz, MR; Loegering, DJ; Mazurkiewicz, JE; Mehta, S; Saito, N | 1 |
| Bodis, S; Fabbro, D; Glanzmann, C; Lowe, SW; Pruschy, M; Rocha, S; Soengas, MS; Winterhalter, K | 1 |
| Bodis, S; Fabbro, D; Glanzmann, C; Hegyi, I; Oehler, C; Pruschy, M; Resch, H; Rocha, S; Zaugg, K | 1 |
| Balkwill, F; Blackie, R; Braybrooke, JP; Caponigro, F; Dutreix, C; Ganesan, TS; Graf, P; Harris, AL; Kaye, SB; Man, A; McDonald, AC; Propper, DJ; Talbot, DC; Thavasu, P; Twelves, C | 1 |
| Dworakowska, D; Dworakowski, R; Kocic, I; Petrusewicz, J | 1 |
| Cocker, HA; Kelland, LR; Pinkerton, CR; Pritchard-Jones, K; Tiffin, N | 1 |
| Bodis, S; Fabbro, D; Glanzmann, C; Hemmings, B; Pruschy, M; Rocha, S; Schubiger, PA; Tenzer, A; Zingg, D | 1 |
| Kaye, SB; Swannie, HC | 1 |
| Champain, K; Csermak, K; Ganeshaguru, K; Gordon, M; Hart, SM; Hoffbrand, AV; Jones, DT; Man, A; Mehta, AB; Prentice, HG; Virchis, AE; Wickremasinghe, RG | 1 |
| Brandt-Rauf, PW; Chie, L; Chung, DL; Kanovsky, M; Michl, J; Pincus, MR; Sivendran, S; Smith, S; Way, D | 1 |
| Champain, K; Csermak, K; Fabbro, D; Fletcher, L; Ganeshaguru, K; Hart, S; Jones, D; Man, A; Mehta, A; Meyer, T; Prentice, HG; Virchis, A; Wickremasinghe, R; Wright, F; Yap, A | 1 |
| Boulton, C; Fabbro, D; Gilliland, DG; Griffin, JD; Kelly, LM; Manley, P; Meyer, T; Weisberg, E | 1 |
| Kagota, S; Kunitomo, M; Nakamura, K; Shinozuka, K; Yamaguchi, Y; Yoshikawa, N | 1 |
| Armstrong, SA; Den Boer, ML; Fletcher, JA; Golub, TR; Griffin, JD; Kersey, JH; Korsmeyer, SJ; Kung, AL; Mabon, ME; Pieters, R; Sallan, SE; Silverman, LB; Stam, RW | 1 |
| Duyster, J; Grundler, R; Miething, C; Peschel, C; Steudel, C; Thiede, C | 1 |
| Amaral, SM; Boulton, CL; Cools, J; Coutre, SE; Curley, DP; DeAngelo, DJ; Duclos, N; Fabbro, D; Gilliland, DG; Gotlib, J; Griffin, JD; Kutok, JL; Lee, BH; Legare, RD; Manley, PW; Marynen, P; Meyer, T; Neuberg, D; Rowan, R; Stone, RM; Stover, EH; Weisberg, E; Williams, IR | 1 |
| Campochiaro, PA; Melia, M; Saishin, Y; Seo, MS; Takahashi, K | 1 |
| Ahlheim, M; Bodmer, D; Brazzell, RK; Callahan, K; Campochiaro, PA; Kane, F; Lai, H; Saishin, Y; Schoch, C; Silva, RL | 1 |
| Bagrintseva, K; Eichenlaub, S; Ellwart, JW; Hiddemann, W; Kohl, TM; Schnittger, S; Schwab, R; Spiekermann, K | 1 |
| Campbell, A; Clark, JW; Deluca, P; Eder, JP; Garcia-Carbonero, R; LoRusso, P; Puchalski, TA; Rothermel, J; Ryan, DP; Supko, JG; Wozniak, A | 1 |
| Bodis, S; Hofstetter, B; Pruschy, M; Riesterer, O; Tenzer, A; Vuong, V; Zingg, D | 1 |
| Berthaud, P; Faivre, S; Henriksson, R; Le Chevalier, T; Monnerat, C; Novello, S; Raymond, E | 1 |
| Boulton, C; Gilliland, DG; Griffin, JD; Gu, TL; Mohi, MG; Neel, BG; Neuberg, D; Sternberg, DW | 1 |
| Campochiaro, PA | 1 |
| Annavarapu, S; Bali, P; Bhalla, K; Cohen, P; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Tao, J; Vishvanath, A | 1 |
| Bo, R; Boggon, TJ; DeAngelo, DJ; Eck, MJ; Fox, EA; Galinsky, I; Gilliland, DG; Griffin, JD; Herman, P; Jiang, J; Jonasova, A; Lee, JC; Meyerson, M; Paez, JG; Sellers, WR; Stone, RM; Weisberg, E; Wolpin, BM | 1 |
| Inoguchi, T; Kobayashi, K; Matsumoto, S; Nawata, H; Sekiguchi, N; Sonta, T; Tsubouchi, H; Utsumi, H | 1 |
| Annavarapu, S; Atadja, P; Bali, P; Bhalla, K; Cohen, P; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Tao, J; Vishvanath, A | 1 |
| Furue, M; Miwa, Y; Morimoto, S; Nakazono-Kusaba, A; Sasaguri, T; Takahashi-Yanaga, F | 1 |
| Clark, J; Cohen, P; DeAngelo, DJ; Estey, E; Fox, EA; Galinsky, I; Gilliland, DG; Grandin, W; Griffin, JD; Klimek, V; Lebwohl, D; Neuberg, D; Nimer, SD; Stone, RM; Wang, Y | 1 |
| Clark, JJ; Cools, J; Fabbro, D; Furet, P; Gilliland, DG; Griffin, JD; Marynen, P; Mentens, N | 1 |
| Adelsperger, J; Banerji, L; Chen, J; Coburn, A; Cohen, PS; Cohen, S; Deangelo, DJ; Duclos, N; Fabbro, D; Fletcher, JA; Galinsky, I; Gilliland, DG; Griffin, JD; Huntly, B; Kutok, JL; Lee, BH; Meyer, T; Okabe, R; Roesel, J; Stone, RM; Wadleigh, M; Williams, IR; Xiao, S | 1 |
| Cools, J; Debiec-Rychter, M; Dumez, H; Hagemeijer, A; Marynen, P; Mentens, N; Prenen, H; Roesel, J; Sciot, R; Stul, M; Van Oosterom, A; Vranckx, H; Wasag, B | 1 |
| Berdel, WE; Brandts, C; Choudhary, C; Fischer, T; Kindler, T; Müller-Tidow, C; Sargin, B; Schwäble, J; Serve, H; Tickenbrock, L | 1 |
| Hemström, TH; Joseph, B; Lewensohn, R; Schulte, G; Zhivotovsky, B | 1 |
| Adelsperger, J; Clark, JJ; Fabbro, D; Gilliland, DG; Griffin, JD; Growney, JD; Stone, R | 1 |
| Zhang, GS | 1 |
| Brausch, I; Förstermann, U; Hergert, SM; Huang, Q; Lehr, HA; Li, H; Mang, C; Schäfer, SC; Yao, Y | 1 |
| Borie, DC; Reitz, BA; Si, MS | 1 |
| Cools, J | 1 |
| Armstrong, SA; Beverloo, HB; de Lorenzo, P; den Boer, ML; Horstmann, M; Nollau, P; Pieters, R; Sallan, SE; Schneider, P; Stam, RW; Valsecchi, MG; van der Voort, E | 1 |
| Arber, DA; Berubé, C; Chen, CC; Cohen, PS; Coutré, SE; Durocher, JA; Galli, SJ; George, TI; Gilliland, DG; Gotlib, J; Growney, JD; Heinrich, MC; Kajiguchi, T; Lichy, JH; Lilleberg, SL; Neckers, L; Ruan, J; Wang, Y; Williams, C | 1 |
| Chiaretti, S; Diverio, D; Foa, R; Guarini, A; Maggio, R; Porzia, A; Ritz, J; Tatarelli, C; Torelli, GF; Vitale, A | 1 |
| Bahlis, NJ; Boise, LH; Gerson, SL; Koc, ON; Lee, K; Miao, Y | 1 |
| Adelsperger, J; Anderson, KC; Chen, J; Coburn, A; Cohen, S; Duclos, N; Fabbro, D; Gilliland, DG; Griffin, JD; Huntly, BJ; Kutok, JL; Lee, BH; Mitsiades, CS; Moore, S; Okabe, R; Williams, IR | 1 |
| Amaral, SM; Anastasiadou, E; Boulton, CL; Curley, DP; Duclos, N; Fabbro, D; Gilliland, DG; Griffin, JD; Huntly, BJ; Joseph, SW; Lee, BH; Williams, IR | 1 |
| Brandts, C; Breitenbuecher, F; Cohen, PS; Ehninger, G; Feldman, E; Fischer, T; Giles, F; Heidel, F; Huber, C; Kasper, S; Kindler, T; Lipka, DB; Nimer, S; Roesel, J; Schiller, GJ; Serve, H; Solem, FK; Stone, RM; Thiede, MH; Wang, Y | 1 |
| Aichberger, KJ; Böhm, A; Derdak, S; Fabbro, D; Gleixner, KV; Gruze, A; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
| Bagrintseva, K; Ellwart, JW; Hiddemann, W; Hopfner, KP; Reindl, C; Schnittger, S; Spiekermann, K; Vempati, S; Wenig, K | 1 |
| Kiyoi, H | 4 |
| Berdel, WE; Müller-Tidow, C; Serve, H; Tickenbrock, L | 1 |
| Hemström, TH; Sandström, M; Zhivotovsky, B | 1 |
| August, M; Brausch, I; Closs, EI; Förstermann, U; Gödtel-Armbrust, U; Habermeier, A; Li, H; Münzel, T; Oelze, M; Witte, K | 1 |
| Brown, P; Cohen, P; Deangelo, D; Estey, E; Galinsky, I; Giles, F; Kantarjian, H; Karp, JE; Levis, M; Pham, R; Roesel, J; Small, D; Smith, BD; Stine, A; Stone, R; Wang, Y | 1 |
| Austin, SJ; Burnett, AK; Gilkes, AF; Knapper, S; Mills, KI; Walsh, V | 1 |
| Bowtell, D; Cohen, PS; Copeman, M; Gore, M; House, C; Lynch, K; Millward, MJ; Olver, IN; Wang, Y; Webster, L; Yap, A; Zalcberg, J | 1 |
| Khong, T; Sharkey, J; Spencer, A | 1 |
| Carter, GI; Grundy, M; Hunter, HM; Lloyd-Lewis, B; Massip, AM; Pallis, M; Russell, NH; Seedhouse, CH; Shang, S | 1 |
| Catley, L; Fabbro, D; Griffin, JD; Hall-Meyers, E; Jiang, J; Kung, AL; Manley, PW; Moreno, D; Podar, K; Ray, A; Weisberg, E; Wright, RD | 1 |
| Agis, H; Aichberger, KJ; Gleixner, KV; Gruze, A; Krauth, MT; Mayerhofer, M; Müllauer, L; Pickl, WF; Selzer, E; Sillaber, C; Valent, P; Wacheck, V | 1 |
| Chung, WH; Han, K; Han, KT; Kim, M; Kim, Y; Lim, J; Park, IY | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kirito, K; Mano, H; Matsuo, Y; Odgerel, T; Sato, Y; Tsunoda, S; Vu, HA | 1 |
| Ashman, LK; Baleato, RM; Byrnes, EM; Griffith, R; Lyons, AB; Odell, AF; Roberts, KG | 1 |
| von Mehren, M | 1 |
| Hashimoto, K; Inoue, H; Itakura, M; Miyatake, K; Nakano, S; Takaku, H; Takata, Y; Yasui, N | 1 |
| Catley, L; Cools, J; Gilliland, G; Griffin, JD; Hall-Meyers, E; Jiang, J; Kung, AL; McMillin, DW; Mitsiades, C; Moreno, D; Ray, A; Tran, M; Weisberg, E; Wright, RD; Zawel, L | 1 |
| Büchler, MW; Büchler, P; El Fitori, J; Friess, H; Giese, NA; Herr, I; Hines, OJ; Ludwig, R; Quentmeier, H; Su, Y | 1 |
| Barry, EV; Clark, JJ; Cools, J; Gilliland, DG; Roesel, J | 1 |
| Chung, EJ; Kajiguchi, T; Kiyoi, H; Lee, S; Levis, MJ; Naoe, T; Neckers, L; Stine, A; Trepel, JB | 1 |
| Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
| Andersson, A; Bengtzen, S; Deneberg, S; Fioretos, T; Jonsson-Videsäter, K; Lehmann, S; Möllgård, L; Nahi, H; Paul, C | 1 |
| Aichberger, KJ; Baumgartner, C; Fabbro, D; Gleixner, KV; Gruze, A; Lee, FY; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
| de Vries, AC; den Boer, ML; Haas, OA; Kratz, CP; Niemeyer, CM; Pieters, R; Schneider, P; Stam, RW; van den Heuvel-Eibrink, MM; van Wering, ER | 1 |
| Berger, R; Bernard, OA; Boggon, TJ; Deininger, MW; Döhner, H; Döhner, K; Druker, BJ; Ebert, BL; Fröhling, S; Gilliland, DG; Golub, TR; Griffin, JD; Heinrich, MC; Jiang, J; Lee, BH; Levine, RL; Loriaux, M; Schittenhelm, MM; Scholl, C; Stone, RM; Teckie, S | 1 |
| Furukawa, Y; Futaki, K; Kano, Y; Kikuchi, J; Odgerel, T; Shimizu, R; Wada, T | 1 |
| Bui, B; Italiano, A | 1 |
| Ehninger, G; Illmer, T | 1 |
| Amstutz, R; Ebauer, M; Fabbro, D; Haneke, T; Kleinert, P; Niggli, FK; Oehler-Jänne, C; Schäfer, BW; Troxler, H; Wachtel, M | 1 |
| Graf, P; Kisicki, JC; Schran, H; Wang, Y; Yin, OQ | 1 |
| Battaglia, S; Blanchard, F; Brounais, B; Charrier, C; Chipoy, C; Heymann, D; Mori, K; Pilet, P; Rédini, F; Richards, CD | 1 |
| Barrett, R; Bold, G; Cools, J; Daley, JF; Fox, E; Furet, P; Galinsky, I; Gilliland, G; Griffin, JD; Hall-Meyers, E; Jiang, J; Kung, AL; Lazo-Kallanian, S; Moreno, D; Nelson, E; Ray, A; Roesel, J; Stone, R; Weisberg, E; Wright, RD | 1 |
| Duncan, JS; Kerman, K; Kraatz, HB; Litchfield, DW; Song, H | 1 |
| Schran, H; Wang, Y; Yin, OQ | 1 |
| Eliasson, P; Jönsson, JI; Kraft, M; Labi, V; Lam, EW; Nordigården, A; Villunger, A | 1 |
| Böhmer, FD; Breitenbuecher, F; Carius, B; Fischer, T; Huber, C; Kasper, S; Kindler, T; Markova, B; Masson, K; Rönnstrand, L; Stauder, T | 1 |
| Böhmer, FD; Duyster, J; Fischer, T; Grundler, R; Heidel, F; Huber, C; Kancha, RK; Lipka, DB; Mahboobi, S; Mirea, FK; Naumann, M | 1 |
| Tallman, M | 1 |
| Gore, SD | 1 |
| Karp, J | 1 |
| Aberg, E; Duyster, J; Engh, RA; Peschel, C; Sänger, J; von Bubnoff, N | 1 |
| Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Chao, DK; Chen, YJ; Clifford Chao, KS; Huang, YC | 1 |
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Burnett, A; Lo-Coco, F; Löwenberg, B; Sanz, M | 1 |
| Aichberger, KJ; Baumgartner, C; Cerny-Reiterer, S; Ferenc, V; Gleixner, KV; Gruze, A; Kneidinger, M; Mayerhofer, M; Mirkina, I; Peter, B; Pickl, WF; Sillaber, C; Valent, P | 1 |
| Baumgartner, C; Herrmann, H; Kneidinger, M; Krauth, MT; Mirkina, I; Valent, P | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Büchner, T; Krug, U; Lübbert, M | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Ehninger, G; Koch, S; Mohr, B; Oelschlägel, U; Steudel, C; Stölzel, F; Thiede, C | 1 |
| Ashman, LK; Griffith, R; Mashkani, B | 1 |
| Amstutz, RA; Hecker, RM; Niggli, FK; Schäfer, BW; Wachtel, M; Walter, D | 1 |
| Castells, MC; Liu, A; Ross, JJ; Saavedra, A; Vleugels, RA | 1 |
| Gleixner, KV; Hadzijusufovic, E; Mirkina, I; Peter, B; Pickl, WF; Schuch, K; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Ahmad, R; Galinsky, I; Kharbanda, S; Kufe, D; Liu, S; Meyer, C; Nelson, E; Stone, R; Weisberg, E | 1 |
| Chen, YJ; Huang, YC; Shieh, HR | 1 |
| Deangelo, DJ; Dutreix, C; Ehninger, G; Estey, E; Feldman, EJ; Fischer, T; Fox, E; Galinsky, I; Giles, FJ; Gilliland, DG; Huntsman-Labed, A; Klimek, VM; Lanza, C; Nimer, SD; Schiller, GJ; Stone, RM; Virkus, J | 1 |
| Barrett, R; Christie, AL; Daley, JF; Frank, D; Galinsky, I; Griffin, JD; Kung, AL; Lazo-Kallanian, S; Nelson, E; Porter, D; Ray, A; Stone, R; Straub, C; Weisberg, E; Zawel, L | 1 |
| Affolter, M; Fent, K; Hoeger, B; Küry, M; Lenard, A; Oggier, DM | 1 |
| Karlsson, M; Korenovska, O; Norberg, E; Orrenius, S; Silberberg, G; Szydlowski, S; Uhlén, P; Zhivotovsky, B | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Brandal, S; Carter, M; Kapur, R; Lee, YN; McDevitt, MA; Mendell, JT; Metcalfe, DD; Noel, P; Takemoto, CM; Wentzel, E | 1 |
| Drabkin, HA; Gadgil, S; Hermanova, I; Kornblau, SM; Qiu, YH; Starkova, J; Zhang, N | 1 |
| Pardanani, A | 3 |
| Akin, C; DeRemer, DL; Ustun, C | 1 |
| Bennett, KL; Cerny-Reiterer, S; Gleixner, KV; Gotlib, J; Hadzijusufovic, E; Hörmann, G; Horny, HP; Mayerhofer, M; Meyer, RA; Mitterbauer-Hohendanner, G; Pickl, WF; Reiter, A; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Chabner, BA; Fathi, AT | 1 |
| Adamia, S; Barrett, R; Daley, JF; Fox, E; Frank, D; Griffin, JD; Nelson, E; Ray, A; Sattler, M; Weisberg, E; Zhang, C | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Alemu, L; Anderson, S; Brinster, L; Gilliland, DG; Hoogstraten-Miller, S; Kamikubo, Y; Kench, M; Kirby, M; Liu, PP; Melenhorst, JJ; Zhao, L | 1 |
| Kawahara, I; Kinugawa, S; Kobayashi, Y; Koide, M; Mizoguchi, T; Muto, A; Nakamura, M; Ninomiya, T; Takahashi, N; Udagawa, N; Yasuda, H | 1 |
| del Corral, A; Dutreix, C; Harrell, R; Huntsman-Labed, A; Lorenzo, S; Morganroth, J; Wang, Y | 1 |
| Boro, A; Niggli, FK; Oesch, S; Prêtre, K; Rechfeld, F; Schäfer, BW; Thalhammer, V; Wachtel, M | 1 |
| Bronson, R; Christie, AL; Daley, JF; Galinsky, I; Gray, N; Griffin, JD; Hur, W; Kung, AL; Liu, Q; Mitsiades, C; Nelson, E; Sanda, T; Sattler, M; Smith, R; Stone, R; Weisberg, E; Zhao, Z | 1 |
| Breitenbuecher, F; Guyot, M; Hoffarth, S; Höhn, Y; Meiler, J; Schuler, M; Wesarg, E | 1 |
| Cortes, J; Daver, N | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Cortes, J; DeAngelo, DJ; del Corral, A; Dutreix, C; Ehninger, G; Fischer, T; Giles, F; Huntsman-Labed, A; Kantarjian, HM; Paquette, R; Schiffer, CA; Schiller, G; Stone, RM | 1 |
| Bhatt, L; Chang, CJ; Cotter, TG; Dickinson, BC; Gough, DR; Naughton, R; Stanicka, J; Woolley, JF | 1 |
| Böhmer, FD; Bolck, HA; Buchwald, M; Bug, G; Heinzel, T; Krämer, OH; Pietschmann, K; Polzer, H; Spiekermann, K; Spielberg, S | 1 |
| Corcoran, A; Cotter, TG | 1 |
| Gershburg, E; Gershburg, S; Goswami, R; Satorius, A | 1 |
| Chi, HT; Kano, Y; Ly, BT; Sato, Y; Tojo, A; Watanabe, T | 1 |
| Chan, E; Heffron, TP; La, H; Lee, HJ; Malek, S; Merchant, M; Pirazzoli, V; Politi, K; Schaefer, G; Settleman, J; Shao, L; Sideris, S; Ubhayakar, S; Yauch, RL; Ye, X | 1 |
| Efazat, G; Hyrslova Vaculova, A; Kaminskyy, VO; Lewensohn, R; Moshfegh, A; Rodriguez-Nieto, S; Ståhl, S; Viktorsson, K; Zhivotovsky, B | 1 |
| Bornhäuser, M; Brenner, S; Brors, B; Ehninger, G; Heiderich, C; Hofmann, WK; Jacobi, A; Koch, S; Ortlepp, C; Ryser, M; Steudel, C; Thiede, C | 1 |
| Albers, C; Duyster, J; Illert, AL; Leischner, H; Peschel, C; Verbeek, M; von Bubnoff, N; Yu, C | 1 |
| Bartels, J; Haller, H; Kiyan, Y; Laudeley, R; Meier, M; Menne, J; Park, JK; Shushakova, N | 1 |
| Galinsky, I; Gray, N; Griffin, JD; Liu, F; Liu, Q; Mitsiades, C; Nelson, E; Nicolais, M; Nonami, A; Sattler, M; Smith, RW; Stone, R; Weisberg, E; Zhang, J; Zhang, X | 1 |
| Blatt, K; Gleixner, KV; Hadzijusufovic, E; Peter, B; Radia, D; Reiter, A; Suppan, V; Valent, P | 1 |
| Bharate, SB; Sawant, SD; Singh, PP; Vishwakarma, RA | 1 |
| Bennett, KL; Borgdorff, V; Breitwieser, FP; Colinge, J; Gridling, M; Müller, AC; Rix, U; Superti-Furga, G; Wagner, C; Wagner, SN; Winter, GE | 1 |
| Bai, Y; Bandara, G; Brittain, E; Chan, EC; Dyer, KD; Gilfillan, AM; Klion, AD; Maric, I; Metcalfe, DD; Scott, L; Simakova, O; Wilson, TM | 1 |
| Abhyankar, S; Aljitawi, O; Bhalla, KN; Dutreix, C; Fiskus, W; Fleming, A; Ganguly, S; Kambhampati, S; McGuirk, JP; Reyes, R; Wick, J; Williams, CB | 1 |
| Chi, HT; Hara, Y; Kano, Y; Ly, BT; Nakano, K; Sato, Y; Watanabe, T; Yamagishi, M | 1 |
| Berdel, WE; Blum, H; Bohlander, SK; Braess, J; Büchner, T; Dufour, A; Graf, A; Greif, PA; Herold, T; Hiddemann, W; Hopfner, KP; Kakadia, PM; Konstandin, NP; Krebs, S; Ksienzyk, B; Opatz, S; Polzer, H; Sauerland, MC; Schneider, S; Spiekermann, K; Vosberg, S; Woermann, BJ; Zellmeier, E | 1 |
| Albouhair, S; Lavau, C; Morgado, E | 1 |
| Dutreix, C; Lorenzo, S; Munarini, F; Roesel, J; Wang, Y | 1 |
| Bai, Y; Bennett, K; Colinge, J; Eschrich, S; Fang, B; Grebien, F; Haura, EB; Kim, JY; Koomen, J; Li, J; Okamoto, I; Qian, X; Rawal, B; Rix, U; Schell, M; Song, L; Stukalov, A; Superti-Furga, G; Winter, G; Yoshida, T; Zhang, G | 1 |
| Lancet, JE | 1 |
| Amin, A; Bourget, P; Cabaret, L; Carvalhosa, A; Chandesris, MO; Damaj, G; Frenzel, L; Hermine, O; Hirsch, I; Lortholary, O; Merlette, C; Mogenet, A; Vidal, F | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Brunner-Weinzierl, M; Fischer, T; Frey, S; Hebel, K; Heidel, FH; Höding, C; Isermann, B; Kliche, S; Lipka, DB; Mack, TS; Parkner, A; Perner, F; Pils, MC; Ranjan, S; Schnöder, TM; Schraven, B; Wagner, MC; Wolleschak, D | 1 |
| Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
| Dutreix, C; Lorenzo, S; Wang, Y | 1 |
| Chen, PM; Chiou, TJ; Gau, JP; Hong, YC; Hsiao, LT; Liu, CY; Liu, JH; Lu, DY; Tzeng, CH; Yu, YB | 1 |
| Frater, JL; Hassan, A; Kreisel, FH; Xu, X | 1 |
| Metzgeroth, G; Reiter, A; Schwaab, J | 1 |
| Barra, FF; Costa, FF; de Melo Campos, P; Duarte, AS; Lorand-Metze, I; Machado-Neto, JA; Olalla Saad, ST; Rogers, HJ; Scopim-Ribeiro, R; Tabarroki, A; Tiu, RV; Traina, F; Vassalo, J; Visconte, V | 1 |
| Courts, C; Gallala, H; Janzen, V; Kraus, D; Nowak, M; Perner, S; Probstmeier, R; Veit, N; Winter, J | 1 |
| Few, LL; Kuan, CS; See Too, WC; Yee, YH | 1 |
| Andreeff, M; Borthakur, G; Cortes, J; Daver, N; Durand, M; Estrov, Z; Garcia-Manero, G; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Rajkhowa, T; Ravandi, F; Strati, P | 1 |
| Chi, HT; Dung, PC; Ly, BT; Sato, Y; Vu, HA; Xinh, PT | 1 |
| Cotter, TG; Russell, EG; Stanicka, J; Woolley, JF | 1 |
| Baselga, J; Bennett, KL; Colinge, J; Ibrahim, Y; Kerzendorfer, C; Klepsch, F; Kubicek, S; Lechtermann, H; Leitner, E; Macho-Maschler, S; Mair, B; Muellner, MK; Müller, AC; Nijman, SM; Rix, U; Serra, V; Superti-Furga, G; Trefzer, C | 1 |
| Cooper, BW; Craig, MD; Creger, RJ; Hamadani, M; Kindwall-Keller, TL; Lazarus, HM; Tse, WW | 1 |
| Abuzenadah, AM; Al-Maghrabi, JA; Al-Qahtani, MH; Chaudhary, AG; Farsi, HM; Gari, MA; Karim, S; Mirza, Z; Schulten, HJ | 1 |
| Ebihara, Y; Hanada, S; Imai, K; Konishi, C; Matsuzaka, E; Mochizuki, S; Nakauchi, H; Otsu, M; Takagi, H; Tsuji, K; Yamamoto, S | 1 |
| Åberg, E; Alexeeva, M; Engh, RA; Rothweiler, U | 1 |
| Liu, S; Molina, JR; Pang, J; Shen, N; Yan, F; Yang, P | 1 |
| Adelstein, RS; Chen, L; Conti, MA; Kwan, R; Looi, K; Omary, MB; Snider, NT; Tao, GZ; Weerasinghe, SV; Xie, Q | 1 |
| Kamada, S; Kawai, M; Kikkawa, U; Nakashima, A | 1 |
| Antonakos, B; Barys, L; Cooke, VG; Cowens, K; Galinsky, I; Griffin, JD; Halilovic, E; Ito, M; Jeay, S; McDonough, SM; Nelson, E; Nonami, A; Ren, T; Sanda, T; Sattler, M; Simkin, I; Stone, R; Weisberg, E; Wiesmann, M; Wuerthner, JU; Yuan, J | 1 |
| Bennett, KL; Blatt, K; Dutreix, C; Eisenwort, G; Gridling, M; Hadzijusufovic, E; Hoermann, G; Manley, PW; Peter, B; Radia, D; Reiter, A; Rix, U; Roesel, J; Schwaab, J; Stefanzl, G; Superti-Furga, G; Valent, P; Winter, GE | 1 |
| Smith, LL | 1 |
| Sun, WL; Wang, YY | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Dziadosz, M; Fischer, T; Lipka, DB; Wagner, MC | 1 |
| Akin, C; Awan, FT; George, TI; Gotlib, J; Hartmann, K; Hermine, O; Hexner, E; Horny, HP; Huntsman Labed, A; Kluin-Nelemans, HC; Mauro, MJ; Reiter, A; Sotlar, K; Stanek, EJ; Sternberg, DW; Valent, P; Villeneuve, M | 1 |
| Barete, S; Besnard, S; Beyne-Rauzy, O; Bourget, P; Brouzes, C; Canioni, D; Chandesris, MO; Chantepie, S; Cherquaoui, Z; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Durupt, S; Faure, C; Frenzel, L; Gressin, R; Gyan, E; Hamidou, M; Hanssens, K; Hermine, O; Jeandel, PY; Launay, D; Lhermitte, L; Lortholary, O; Niault, M; Ranta, D; Schiffmann, A | 1 |
| Camós, M; Català, A; Caviedes-Cárdenas, L; Fernández-Calotti, P; Malatesta, R; Pastor-Anglada, M; Rives, S; Vega-García, N | 1 |
| Bauer, K; Cerny-Reiterer, S; Hadzijusufovic, E; Hoermann, G; Pirker, A; Reifinger, M; Valent, P; Willmann, M | 1 |
| Ao, Z; Chen, L; Liu, L; Liu, S; Tan, X; Yao, X; Zhu, R | 1 |
| Chen, SR; He, XP; Huang, ZJ; Li, JP; Lu, XS; Qin, LS; Shao, Y; Sun, WH; Wang, DD; Zhou, YC | 1 |
| Bruserud, Ø; Nepstad, I; Tvedt, TH | 1 |
| Bennett, KL; Brunak, S; Emdal, KB; Huber, KV; Kovar, H; Mutz, C; Olsen, JV; Papamarkou, T; Radic-Sarikas, B; Superti-Furga, G; Toretsky, JA; Tsafou, KP | 1 |
| Gatlik, E; Gu, H; He, H; Heimbach, T; Klein, K; Lin, W; Tedesco, V; Tran, P; Zhang, J | 1 |
| Levis, M | 1 |
| Patnaik, MM | 2 |
| Kim, ES | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; de Witte, T; Döhner, H; Döhner, K; Ehninger, G; Ganser, A; Geyer, S; Klisovic, RB; Krauter, J; Larson, RA; Laumann, K; Lo-Coco, F; Mandrekar, SJ; Marcucci, G; Medeiros, BC; Niederwieser, D; Prior, TW; Sanford, BL; Sanz, MA; Schlenk, RF; Serve, H; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Wei, A | 1 |
| Albano, F; Bavaro, L; Calogero, R; Cavo, M; Ciceri, F; De Benedittis, C; Delledonne, M; Elena, C; Fontana, MC; Gangemi, D; Guadagnuolo, V; Haferlach, T; Mancini, M; Manfrini, M; Martinelli, G; Meggendorfer, M; Merante, S; Morigi, F; Padella, A; Pagano, L; Papayannidis, C; Poletti, G; Riccioni, L; Rondoni, M; Savini, P; Scaffidi, L; Soverini, S; Specchia, G; Tosi, P; Valent, P; Zago, E; Zanotti, R | 1 |
| Das, M | 1 |
| Gotlib, J | 1 |
| Berube, C; Corless, C; Coutre, S; DeAngelo, DJ; Dutreix, C; George, TI; Gotlib, J; Graubert, TJ; Langford, C; Liedtke, M; Linder, A; Ma, J; Medeiros, B; Merker, JD; Perkins, C; Ruffie, PA; Sternberg, D; Westervelt, P | 1 |
| Aschenbrenner, DS | 1 |
| Sheridan, C | 1 |
| Akin, C; Arock, M; Blatt, K; George, TI; Gleixner, KV; Gotlib, J; Hartmann, K; Hermine, O; Horny, HP; Kluin-Nelemans, HC; Manley, PW; Peter, B; Reiter, A; Sotlar, K; Sperr, WR; Valent, P | 1 |
| Estey, E; Percival, ME | 1 |
| Kayser, S; Levis, MJ; Schlenk, RF | 1 |
| Pollyea, DA; Stansfield, LC | 1 |
| Tiong, IS; Wei, AH | 2 |
| DeAngelo, DJ; Luskin, MR | 1 |
| He, JJ; Liu, CY; Su, L; Sun, WL; Wang, YY; Zhang, W | 1 |
| Döhner, H; Larson, RA; Stone, RM | 1 |
| Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L | 1 |
| Eskazan, AE | 1 |
| Kumar, L; Sahoo, RK | 1 |
| Hughes, TP; Rasko, JEJ | 1 |
| Stone, RM | 1 |
| Griffin, JD; Manley, PW; Sattler, M; Weisberg, E | 1 |
| Kim, M; Williams, S | 1 |
| Arock, M; Berger, D; Bibi, S; Blatt, K; Eisenwort, G; Hadzijusufovic, E; Herrmann, H; Hoermann, G; Hoffmann, T; Horny, HP; Jawhar, M; Moriggl, R; Peter, B; Reiter, A; Schwaab, J; Sotlar, K; Sperr, WR; Stefanzl, G; Valent, P; Willmann, M; Wingelhofer, B; Zuber, J | 1 |
| Stone, RM; Yogarajah, M | 1 |
| Garcia, JS; Percival, ME | 1 |
| Abdel-Wahab, O; Barbui, T; Cortes, JE; Gale, RP; Gotlib, J; Hehlmann, R; Khoury, HJ; Koschmieder, S; Mauro, M; Mesa, R; Mughal, TI; Radich, JP; Saglio, G; Saussele, S; Van Etten, RA; Verstovek, S | 1 |
| Tollkuci, E | 1 |
| de Monchy, JGR; Kluin-Nelemans, JC; Mulder, AB; Oude Elberink, JNG; Rosati, S; Span, LFR; van Anrooij, B | 1 |
| Chen, B; Zhou, F | 1 |
| Asami, Y; Crump, A; Ōmura, S | 1 |
| Backman, JT; Filppula, AM; Mustonen, TM | 1 |
| Ma, N; Wang, C; Zhou, J; Zhou, Y; Zhu, Y | 1 |
| Marques, MAT; Mueller, BU; Pabst, T; Seipel, K; Sidler, C | 1 |
| Falchi, L; Verstovsek, S | 1 |
| Castells, MC | 1 |
| Le-Rademacher, JG; Mandrekar, SJ; Peterson, RA; Sanford, BL; Stone, RM; Therneau, TM | 1 |
| Cortes, JE; Rytting, ME; Short, NJ | 1 |
| Farrell, AT; Kasamon, YL; Ko, CW; Ma, L; McKee, AE; Nie, L; Pazdur, R; Przepiorka, D; Shord, S; Subramaniam, S; Yang, Y | 1 |
| Caravatti, G; Furet, P; Manley, PW; Roesel, J; Tran, P; Wagner, T; Wartmann, M | 1 |
| Baird, JH; Gotlib, J | 1 |
| Besse, E; Brethon, B; Dufour, C; Dutreix, C; Fagioli, F; Ho, PA; Luciani, M; Pieters, R; Rizzari, C; Söderhäll, S; Stam, RW; Zwaan, CM | 1 |
| Ctortecka, C; Fang, B; Haura, EB; Izumi, V; Kinose, F; Koomen, JM; Kuenzi, BM; Novakova, S; Palve, V; Remsing Rix, LL; Rix, U; Sumi, NJ | 1 |
| Sweet, K; Talati, C | 1 |
| Geswein, L; Mulseh, M; Seddon, A; Tollkuci, E | 1 |
| Campbell, P; Thomas, CM | 1 |
| Bhattacharyya, S; Bonifacio, G; Duchesneau, E; Guerin, A; Joseph, G; Li, N; Ndife, B; Stein, E; Vudumula, U; Xie, J | 1 |
| Alsharedi, M; Dotson, J; Elhamdani, A; Jamil, MO; Petryna, E | 1 |
| Akhtari, M; Alachkar, H; Gutierrez, L; Jang, M; Zhang, T | 1 |
| Mueller, BU; Pabst, T; Seipel, K | 1 |
| Allonca, E; Alvarez-Fernandez, C; Astudillo, A; Braña, A; Costales, P; Estupiñan, O; Fernandez-Garcia, MT; Fernandez-Nevado, L; Hermosilla, MA; Menendez, ST; Moris, F; Oro, P; Perez-Escuredo, J; Rey, V; Rodriguez, A; Rodriguez, R; Santos, L; Tornin, J | 1 |
| Chen, J; Ding, P; Ge, X; Hou, Y; Hu, W; Jiang, Z; Li, L; Lv, X; Wang, Q; Xu, Y; Zeng, H; Zhang, W; Zhou, D | 1 |
| Ambudkar, SV; Hsiao, SH; Hsu, SC; Huang, YH; Lusvarghi, S; Wu, CP | 1 |
| Gaspar, K; Sly, N | 1 |
| Barbui, T; Bose, P; Chen, CC; Deininger, MW; Gotlib, J; Kiladjian, JJ; Koschmieder, S; Kucine, N; Mughal, TI; Pemmaraju, N; Radich, JP; Rampal, R; Saglio, G; Valent, P; Van Etten, RA; Verstovsek, S | 1 |
| Badia, R; Ballana, E; Castellví, M; Clotet, B; Esté, JA; Felip, E; Garcia-Vidal, E; Pujantell, M; Riveira-Muñoz, E | 1 |
| Gremida, A; McCarthy, D; Mir, F | 1 |
| Martynova, A; Merchant, A; Nael, A; O Neill, C; Ramsingh, G; Yaghmour, B; Yaghmour, G | 1 |
| Altmann, H; Arndt, C; Bachmann, M; Bornhäuser, M; Fasslrinner, F; Feldmann, A; Koristka, S; Schmitz, M; von Bonin, M | 1 |
| Perl, AE | 2 |
| Apsel Winger, B; Cortopassi, WA; Ding, L; Esteve-Puig, R; Garrido Ruiz, D; Jacobson, MP; Jang, K; Leyte-Vidal, A; Shah, NP; Zhang, N | 1 |
| Bixby, DL; Marini, BL; Perissinotti, AJ; Weis, TM | 1 |
| Raanani, P; Reiss Mintz, H; Shimony, S; Shoham, A; Shvartser Beryozkin, Y; Wolach, O | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Dubreuil, P; Gokhale, PC; Gray, N; Griffin, JD; Letard, S; Liu, X; Meng, C; Sattler, M; Stone, RM; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Bose, P; Cortes, JE; Dalle, IA; Daver, N; DiNardo, C; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kantarjian, HM; Loghavi, S; Naqvi, K; Patel, K; Pemmaraju, N; Pierce, S; Ravandi, F; Sasaki, K; Short, N; Yalniz, F; Yilmaz, M | 1 |
| Brunner, AM | 1 |
| Dzinic, SH; Edwards, H; Ge, Y; Knight, T; Kushner, J; Lin, H; Ma, J; Polin, L; Qiao, X; Taub, JW; Wang, G; Wang, Y; White, K; Zhao, L; Zhao, S | 1 |
| Schlafer, D | 1 |
| Manley, PW | 1 |
| Levis, MJ | 1 |
| Apel, A; Aviram, A; Berger, T; Frisch, A; Hellmann, I; Koren-Michowitz, M; Moshe, Y; Ofran, Y; Raanani, P; Ram, R; Rozovski, U; Wolach, O; Yaari, S; Yeshurun, M | 1 |
| Thol, F | 1 |
| Alshamleh, I; Günther, UL; Krause, N; Kurrle, N; Richter, C; Schwalbe, H; Serve, H | 1 |
| Coleman, M; Fechter, L; Galinsky, I | 1 |
| Chua, CC; Droogleever, MP; Fong, CY; Grigg, A; Lim, A; Schwarer, A; Singh, J; Ting, SB; Tiong, IS; Wei, AH; Zhang, L | 1 |
| Au, T; Biskupiak, J; Bonifacio, G; Brixner, D; Joseph, G; Kovacsovics, T; Menon, J; Ndife, B; Shami, PJ; Stein, E; Stenehjem, D; Tantravahi, S; Unni, S; Willis, C; Yoo, M | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Wang, ES | 1 |
| Rowe, JM | 1 |
| Kreisle, W; LaMontagne, L; Mancini, R; Petersen, F; Williams, T | 1 |
| Smith, CC | 1 |
| Arenas, A; Ayala, R; Castro, N; Gallardo, M; Gómez-López, G; Leivas, A; Linares, M; Martínez-López, J; Morales, ML; Ortiz-Ruiz, A; Quintela-Fandino, M; Rapado, I; Rodríguez-García, A; Zagorac, I | 1 |
| Arries, CD; Yohe, SL | 1 |
| Ojha, S; Ooi, MG | 1 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Adamia, S; Buhrlage, S; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Toure, AA; Wang, J; Weisberg, E; Winer, E | 1 |
| Daver, NG; Glass, WF; Kala, J; Pankow, JD; Richard-Carpentier, G | 1 |
| Andrieux, G; Boerries, M; Charlet, A; Duyster, J; Endres, C; Follo, M; Herchenbach, D; Keye, P; Rassner, M; Salzer, U; von Bubnoff, N; Waldeck, S | 1 |
| Adamia, S; Buhrlage, SJ; Case, AE; Gokhale, PC; Gray, N; Griffin, JD; Liu, X; Meng, C; Sattler, M; Stone, R; Tiv, HL; Wang, J; Weisberg, E; Yang, J | 1 |
| Blanc, AS; Brandt, P; Cariou, C; Dolph, M; Forsythe, A; Recher, C; Tremblay, G | 1 |
| Cooper, BW; Craig, MD; Gallogly, MM; Kane, DM; Lazarus, HM; Levis, MJ; Metheny, L; Tomlinson, BK; William, BM | 1 |
| Aboualizadeh, F; Akhmanova, A; Al-Awar, R; Aman, A; Datti, A; Drecun, L; Jakopović, M; Joseph, B; Kalaidzidis, Y; Leighl, N; Lyakisheva, A; Marcellus, R; Moran, MF; Park, JH; Pathmanathan, S; Pham, NA; Poda, G; Prakesch, M; Radulovich, N; Rai, A; Sacher, A; Samaržija, M; Saraon, P; Shepherd, FA; Snider, J; Stagljar, I; Thériault, B; Tsao, MS; Uehling, D; Vučetić, A; Vučković, N; Wang, J; Wang, Y; Weiss, K; Wong, V; Wybenga-Groot, LE; Yao, Z; Zerial, M | 1 |
| Lam, SSY; Leung, AYH | 1 |
| George, TI; Gotlib, J; Reiter, A | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Bolstad, B; Dahlseng Håkonsen, G; Dalhus, M; Gisselbrecht, C; Hennik, P; Herberts, C; Kaasboll, T; Meulendijks, D; Pignatti, F; Salmonson, T; Tzogani, K; Verheijen, R; Wangen, T; Yu, Y | 1 |
| Cao, J; Feng, Y; Jia, Y; Jiang, L; Liu, Y; Wang, X; Wang, Z; Yin, H | 1 |
| Akin, C; Awan, FT; George, TI; Gotlib, J; Hartmann, K; Hermine, O; Hexner, E; Horny, HP; Kluin-Nelemans, HC; Knoll, S; Mauro, MJ; Menssen, HD; Redhu, S; Reiter, A; Sotlar, K; Valent, P | 1 |
| Cornely, OA; Koehler, P; Maurer, C; Müller, C; Stemler, J | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Naoe, T | 1 |
| Ballesta-López, O; Martínez-Cuadrón, D; Megías-Vericat, JE; Montesinos, P; Solana-Altabella, A | 1 |
| Barbera, A; Bonifacio, G; Dalovisio, A; Haines, K; Litzow, MR; Perl, AE; Purkayastha, D; Roboz, GJ; Strickland, SA; Sweet, K | 1 |
| Estey, EH | 1 |
| Berger, T; Frisch, A; Gal-Rabinovich, K; Ganzel, C; Hellmann, I; Henig, I; Horesh, N; Leiba, R; Moshe, Y; Neaman, M; Ofran, Y; Weinstein, V; Wolach, O; Yehudai-Ofir, D | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Abdul-Hamil, NA; Cherchione, C; Martinelli, G; Nagarajan, C; Wong, GC | 1 |
| Cerchione, C; Martinelli, G | 1 |
| Büküm, N; Danielisová, P; Milan, J; Morell, A; Novotná, E; Wsól, V | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; Byrd, J; Chen, Y; Cheng, Y; de Witte, TM; Döhner, H; Döhner, K; Du, L; Ehninger, G; Ganser, A; Geyer, SM; Heuser, M; Jansen, JH; Jones, D; Krauter, J; Larson, RA; Lavorgna, S; Lo-Coco, F; Marcucci, G; Medeiros, BC; Niederwieser, D; Nomdedeu, J; Pallaud, C; Piciocchi, A; Prior, T; Sanz, MA; Schlenk, RF; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Voso, MT; Walker, A; Wei, AH | 1 |
| Akin, C; Gotlib, J; Hartmann, K; Kluin-Nelemans, HC; Reiter, A; Valent, P | 1 |
| Beaver, L; Blachly, JS; Brinton, LT; Byrd, JC; Canfield, D; Cannon, M; Cempre, C; Govande, M; Harrington, B; Lapalombella, R; Lehman, A; Orwick, S; Sher, S; Skinner, J; Wasmuth, R; Williams, K; Zhang, P | 1 |
| Charlet, A; Döhner, K; Duyster, J; Endres, C; Fischer, T; Gorantla, SP; Haferlach, T; Heidel, FH; Meggendorfer, M; Rummelt, C; von Bubnoff, N | 1 |
| Fleischmann, M; Heidel, FH; Schnetzke, U; Scholl, S | 1 |
| Bonifacio, G; Deol, A; Fernandez, HF; Haines, K; Hernandez, D; Kim, DDH; Levis, M; Maziarz, RT; Mohan, SR; Patnaik, MM; Purkayastha, D; Rajkhowa, T; Rine, P; Rowley, SD; Scott, BL | 1 |
| Gu, XZ; Liu, JQ; Yu, LQ | 1 |
| Abuín Blanco, A; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Bendaña López, Á; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Melero Valentín, P; Montesinos Fernández, P; Mosquera Orgueira, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
| Blätte, TJ; Bloomfield, CD; Bullinger, L; Cocciardi, S; Döhner, H; Döhner, K; Dolnik, A; Fiedler, W; Gaidzik, VI; Ganser, A; Herzig, J; Heuser, M; Jahn, N; Larson, RA; Lübbert, M; Minucci, S; Panina, E; Paschka, P; Rücker, FG; Salih, HR; Schlenk, RF; Schmalbrock, LK; Schroeder, T; Skambraks, S; Stone, RM; Sträng, E; Stunnenberg, HG; Theis, F; Thol, F; Wulf, G | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Amadori, S; Appelbaum, FR; Bloomfield, CD; Brandwein, JM; de Witte, T; Döhner, H; Döhner, K; Ehninger, G; Galinsky, I; Ganser, A; Gathmann, I; Geyer, S; Huebner, LJ; Klisovic, RB; Krauter, J; Larson, RA; Laumann, K; Mandrekar, SJ; Marcucci, G; Medeiros, BC; Niederwieser, D; Prior, TW; Sanford, BL; Sanz, MA; Schlenk, RF; Serve, H; Sierra, J; Stone, RM; Tallman, MS; Thiede, C; Voso, MT; Wei, AH | 1 |
| Del Principe, MI; Marchesi, F; Menna, P; Minotti, G; Pagano, L; Perrone, S; Salvatorelli, E | 1 |
| Gotlib, J; Shomali, W | 1 |
| Bagnato, G; Cerchione, C; Giannini, MB; Marconi, G; Martinelli, G; Mosquera Orgueira, A; Musuraca, G; Simonetti, G | 1 |
| Amit, O; Avni, B; Bar-On, Y; Krayem, B; Pasvolsky, O; Peretz, G; Raanani, P; Ram, R; Rozovski, U; Shargian, L; Shimony, S; Wolach, O; Yeshurun, M; Zukerman, T | 1 |
| Arellano-Viera, E; Da Via, MC; Einsele, H; Eiring, P; Garitano-Trojaola, A; Gil-Pulido, J; Götz, R; Groll, J; Haertle, L; Hudecek, M; Jetani, H; Kortüm, MK; Kraus, S; Rasche, L; Rhodes, N; Rosenwald, A; Sancho, A; Sauer, M; Teufel, E; Tibes, R; Walz, S | 1 |
| Kuppan, C; Lakka, NS; Ravinathan, P | 1 |
| Beatty, CJ; Ghareeb, ER | 1 |
| Schuh, AC; Tang, K; Yee, KW | 1 |
| Badner, A; Chio, JCT; Fehlings, MG; Hong, J; Khazaei, M; Wang, J; Zavvarian, MM | 1 |
| Alkassis, S; Chi, J; Daoud, L; Rizwan, A | 1 |
| Adam, JP; Bambace, N; Bouchard, P; Otis, AS; Pépin, MA; Soulières, D; Tremblay, Z; Wong, A | 1 |
| Chiewchanvit, S; Chuamanochan, M; Jamjanya, S; Mahanupab, P; Rattanathammethee, T; Tovanabutra, N | 1 |
| Abe, R; Maekawa, Y; Murata, T; Nishida, T; Niwa, M; Obata, Y; Okamoto, K; Shiina, I; Shimonaka, M; Suzuki, T; Tateyama, S; Yamawaki, K | 1 |
| Begna, K; Elliott, MA; Farrukh, F; Gangat, N; Hook, CC; Litzow, MR; Pardanani, A; Shah, MV; Tefferi, A | 1 |
| Bulai Livideanu, C; Casassa, E; Cura, P; Godillot, C; Marguery, MC; Paul, C; Salomon, G; Sévérino-Freire, M; Tournier, E | 1 |
| Iannazzo, S; Pilkington, H; Roskell, N; Smith, S | 1 |
| Abdelmagid, MG; Al-Kali, A; Begna, KH; Farrukh, F; Gangat, N; Larsen, JT; Litzow, MR; Pardanani, A; Reichard, KK; Sher, T; Singh, A; Tefferi, A | 1 |
| Arnán Sangerman, M; Del Mar Tormo Díaz, M; Fernández Moreno, A; García Quintana, A; García-Vidal, C; Olave Rubio, MT; Rodriguez Macias, G; Vendranas, M | 1 |
| Ahmed, F; Ceckova, M; Sorf, A; Sucha, S; Svoren, M; Vagiannis, D; Visek, B | 1 |
| Benner, A; Bullinger, L; Döhner, H; Döhner, K; Fiedler, W; Fransecky, L; Gaidzik, VI; Ganser, A; Götze, K; Hertenstein, B; Heuser, M; Krzykalla, J; Kühn, MWM; Larson, R; Lübbert, M; Machherndl-Spandl, S; Mayer, K; Paschka, P; Ringhoffer, M; Saadati, M; Salih, H; Salwender, H; Schlenk, RF; Schrade, A; Schroeder, T; Stone, R; Theis, F; Thol, F; Tischler, HJ; Weber, D; Westermann, J; Wulf, G | 1 |
| Han, Y; He, S; Li, J; Pang, Y; Yu, L; Zhang, M; Zhao, W | 1 |
| Altman, JK; Chou, WC; Groß-Langenhoff, M; Hasabou, N; Hosono, N; Lee, JH; Levis, MJ; Lu, Q; Martinelli, G; Montesinos, P; Panoskaltsis, N; Perl, AE; Podoltsev, N; Recher, C; Röllig, C; Smith, CC; Strickland, S; Tiu, RV; Yokoyama, H | 1 |
| Has, C; Jahnke, HG; Lin, EW; Magin, TM; Niessen, CM; Omary, MB; Rietscher, K; Rübsam, M | 1 |
| Grosch, K; Ouatas, T; Pathak, D; Sechaud, R; Sinclair, K | 1 |
| Cai, X; Lu, H; Sheng, Y; Weng, XQ; Wu, J; Xi, HM | 1 |
| de Leeuw, DC; Donker, ML; Franssen, LE; Schutte, T; Smits, MM; Stege, CAM | 1 |
| Aquilino, A; Barbieri, E; Barozzi, P; Bettelli, F; Bevini, M; Bresciani, P; Cassanelli, L; Ceccherelli, G; Colaci, E; Colasante, C; Comoli, P; Cordella, S; Cuoghi, A; Forghieri, F; Gilioli, A; Giusti, D; Luppi, M; Maffei, R; Malavolti, R; Manfredini, R; Marasca, R; Martinelli, S; Messerotti, A; Morselli, M; Nasillo, V; Paolini, A; Parisotto, A; Pioli, V; Potenza, L; Pozzi, S; Repaci, G; Riva, G; Tagliafico, E; Trenti, T; Venturelli, D | 1 |
| Banos, A; Béné, MC; Bérard, E; Bertoli, S; Bonmati, C; Carre, M; Chantepie, S; Chebrek, S; Chretien, ML; Cluzeau, T; Debarri, H; Desbrosses, Y; Dombret, H; Dumas, PY; Frayfer, J; Gehlkopf, E; Guièze, R; Guillerm, G; Haiat, S; Heiblig, M; Himberlin, C; Hospital, MA; Jourdan, E; Lambert, J; Laribi, K; Marcais, A; Marchand, T; Mineur, A; Orvain, C; Pasquier, F; Pautas, C; Peterlin, P; Pigneux, A; Raffoux, E; Récher, C; Santagostino, A; Tavernier, E; Turlure, P; Uzunov, M; Vaida, I; Villate, A; Wemeau, M | 1 |
| Avigdor, A; Canaani, J; Gueta, I; Loebstein, R; Marcu-Malina, V; Shimoni, A | 1 |
| Bednarski, JJ; Carter, MC; Nieman, E; Polk, B; Voelker, D | 1 |
| Čerňan, M; Ježíšková, I; Kabut, T; Mayer, J; Podstavková, N; Semerád, L; Szotkowski, T; Weinbergerová, B | 1 |
| Cenin, DA; Donald Harvey Iii, R; Kovacsovics, T; Kurish, HP; Lee, JS; Li, BKT; Lo, M; Patel, S; Prelewicz, S; Schlafer, D; Wagner, CB; Walchack, R; Wasef, B; Ying, J | 1 |
| Brandts, C; Bug, G; Cremer, A; Cremer, S; Enssle, JC; Kouidri, K; Lang, F; Pfaff, S; Serve, H; Steffen, B; Zeiher, A | 1 |
| Bravo, MJ; Brokate-Llanos, AM; Castilla-Ortega, E; Castro-Zavala, A; de Rojas, I; Esteban-Martos, A; García-González, P; González, I; Mañas-Padilla, MDC; Melgar-Locatelli, S; Muñoz, MJ; Pacheco-Sánchez, B; Polvillo, R; Real, LM; Reyes-Engel, A; Rivera, P; Rodriguez de Fonseca, F; Royo, JL; Ruiz, A; Ruiz-Galdon, M | 1 |
| Bengoudifa, BR; Caillot, D; Cluzeau, T; Farkas, F; Gilotti, G; Griskevicius, L; Hodzic, S; Legrand, O; Luppi, M; Minotti, C; Montesinos, P; Rambaldi, A; Sierra, J; Thomas, X; Venditti, A | 1 |
| Cheng, LL; Dai, YT; Fan, LQ; Fang, H; Jiang, L; Liu, F; Liu, H; Liu, MK; Sun, XJ; Wang, L; Weng, XQ; Zhao, WL | 1 |
78 review(s) available for staurosporine and midostaurin
| Article | Year |
|---|---|
Analogs of staurosporine: potential anticancer drugs?
Topics: Alkaloids; Animals; Antineoplastic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Protein Kinase C; Signal Transduction; Staurosporine | 1998 |
Staurosporine analogues - pharmacological toys or useful antitumour agents?
Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Protein Kinase C; Staurosporine | 2000 |
Protein kinase C inhibitors.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Bryostatins; Clinical Trials as Topic; Drug Resistance, Multiple; Enzyme Activation; Enzyme Inhibitors; Humans; Lactones; Macrolides; Molecular Structure; Oligodeoxyribonucleotides, Antisense; Protein Kinase C; Research Design; Staurosporine; Thionucleotides; Tumor Cells, Cultured | 2002 |
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib | 2005 |
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Topics: Animals; Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Staurosporine | 2006 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
[Novel molecularly target therapies for leukemia].
Topics: Antineoplastic Agents; Carbazoles; Farnesyltranstransferase; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia; Piperazines; Quinazolines; Staurosporine | 2007 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
FLT3 inhibition as a targeted therapy for acute myeloid leukemia.
Topics: Acute Disease; Animals; Carbazoles; Drug Evaluation, Preclinical; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid; Molecular Structure; Mutation; Staurosporine | 2009 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
[FLT3 kinase inhibitors for the treatment of acute leukemia].
Topics: Acute Disease; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia; Mutation; Piperazines; Quinazolines; Signal Transduction; Staurosporine | 2010 |
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2011 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Adult; Bone Marrow Examination; Cell Lineage; Cladribine; Clinical Trials as Topic; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Immunophenotyping; Interferon-alpha; Leukemia, Mast-Cell; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Organ Specificity; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Tryptases | 2012 |
Molecular targeted therapy in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine | 2012 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Kinase inhibitors of marine origin.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Aquatic Organisms; Aza Compounds; Carbazoles; Chemistry, Pharmaceutical; Depsipeptides; Furans; Humans; Indoles; Naphthyridines; Peptides, Cyclic; Phosphoinositide-3 Kinase Inhibitors; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyrimidines; Staurosporine; Terpenes | 2013 |
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
[Systemic mastocytosis].
Topics: Biopsy, Needle; Bone Marrow; Cladribine; DNA Mutational Analysis; Humans; Interferon-alpha; Mastocytosis, Systemic; Prognosis; Proto-Oncogene Proteins c-kit; Staurosporine | 2014 |
[Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2015 |
Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.
Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Staurosporine; Stromal Cells; Survival Rate | 2017 |
Midostaurin approved for FLT3-mutated AML.
Topics: Antineoplastic Agents; Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
Midostaurin for the treatment of acute myeloid leukemia.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Prognosis; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2017 |
Midostaurin: First Global Approval.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Approval; Humans; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; United States; United States Food and Drug Administration; Young Adult | 2017 |
Midostaurin: a magic bullet that blocks mast cell expansion and activation.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Humans; Mast Cells; Mastocytosis, Systemic; Multicenter Studies as Topic; Staurosporine | 2017 |
Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.
Topics: Allografts; Consolidation Chemotherapy; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm, Residual; Staurosporine | 2017 |
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Topics: Adult; Animals; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Topics: Administration, Oral; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Drug Approval; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2017 |
Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2017 |
The importance of FLT3 mutational analysis in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gain of Function Mutation; Genetic Testing; Humans; Leukemia, Myeloid, Acute; Prognosis; Protein Domains; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
A concise review of BCL-2 inhibition in acute myeloid leukemia.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Triazines | 2018 |
Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Drug Interactions; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Staurosporine | 2017 |
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Calreticulin; Cardiovascular Diseases; Cell Transformation, Neoplastic; Chronic Disease; Congresses as Topic; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; Mastocytosis, Systemic; Mutation; Myeloproliferative Disorders; Protein Kinase Inhibitors; Remission Induction; Staurosporine; Translational Research, Biomedical | 2018 |
Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features.
Topics: Benzamides; ETS Translocation Variant 6 Protein; Gene Rearrangement; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-ets; Repressor Proteins; Staurosporine; Tumor Microenvironment | 2018 |
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine | 2018 |
Kit Mutations: New Insights and Diagnostic Value.
Topics: Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Skin; Staurosporine | 2018 |
Acute myeloid leukaemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Gemtuzumab; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Patient Selection; Recurrence; Remission Induction; Risk Assessment; Risk Factors; Staurosporine | 2018 |
Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
Topics: Amino Acid Substitution; Clinical Trials as Topic; Humans; Mastocytosis, Systemic; Mutation, Missense; Proto-Oncogene Proteins c-kit; Staurosporine | 2018 |
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines | 2018 |
FLT3 inhibitors in acute myeloid leukemia: Current and future.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Forecasting; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2019 |
Myelodysplastic syndromes and acute myeloid leukemias in the elderly.
Topics: Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Gemtuzumab; Geriatric Assessment; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Staurosporine | 2018 |
Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Management; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Interleukin-2 Receptor alpha Subunit; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Risk Assessment; Staurosporine; Survival Analysis; Transplantation, Homologous; Tryptases | 2019 |
Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
Topics: Antineoplastic Agents; Disease Management; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mutation; Staurosporine | 2019 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.
Topics: Aging; Animals; Congresses as Topic; DNA Mutational Analysis; Humans; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Medical Oncology; Mice; Mutation; Myeloproliferative Disorders; Prognosis; Societies, Medical; Staurosporine; Translational Research, Biomedical; United States | 2019 |
Availability of FLT3 inhibitors: how do we use them?
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzothiazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine | 2019 |
Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
Management of Midostaurin-CYP3A4 Drug-Drug Interactions in Patients With Acute Myeloid Leukemia.
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Staurosporine | 2019 |
Midostaurin for patients with acute myeloid leukemia and FLT3 mutations.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2019 |
[What is recommended in the treatment of acute myeloid leukemia?]
Topics: Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Germany; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Quality of Life; Staurosporine; Sulfonamides | 2019 |
Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Topics: Allografts; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Staurosporine | 2019 |
Will new agents impact survival in AML?
Topics: Aniline Compounds; Disease-Free Survival; Drug Approval; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pyrazines; Staurosporine; Survival Rate; United States | 2019 |
The growing landscape of FLT3 inhibition in AML.
Topics: Allografts; Aniline Compounds; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Middle Aged; Pyrazines; Staurosporine; Stem Cell Transplantation | 2019 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
Overcoming Resistance to FLT3 Inhibitors in the Treatment of
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Drug Therapy, Combination; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Topics: Animals; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Mastocytosis, Systemic; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2020 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Edema; European Union; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Nausea; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Vomiting | 2019 |
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
Topics: Antifungal Agents; Chemoprevention; Drug Interactions; Drugs, Investigational; Humans; Invasive Fungal Infections; Leukemia, Myeloid, Acute; Prognosis; Staurosporine; Triazoles | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytochrome P-450 CYP3A Inhibitors; Drug Approval; Drug Interactions; Drugs, Investigational; Humans; Leukemia, Myeloid, Acute; Long QT Syndrome; Phenylurea Compounds; Protein Kinase Inhibitors; Staurosporine; Sulfonamides | 2020 |
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Sulfonamides; United States | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Topics: Aniline Compounds; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Echinocandins; fms-Like Tyrosine Kinase 3; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Mycoses; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Staurosporine; Triazoles | 2020 |
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin.
Topics: Humans; Mastocytosis, Systemic; Mutation; Quality of Life; Staurosporine | 2021 |
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2020 |
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Topics: Cell Proliferation; Enzyme Inhibitors; Female; Humans; Mast Cells; Mastocytosis, Systemic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2021 |
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Staurosporine | 2021 |
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Risk Assessment; Staurosporine | 2021 |
Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
Topics: Humans; Mastocytosis, Systemic; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2022 |
Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2023 |
36 trial(s) available for staurosporine and midostaurin
| Article | Year |
|---|---|
The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cytokines; Enzyme Inhibitors; Humans; Lymphocytes; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasms; Protein Kinase C; Staurosporine | 1999 |
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Staurosporine | 2001 |
A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Female; Hematologic Neoplasms; Humans; Lymphocyte Count; Lymphoproliferative Disorders; Male; Middle Aged; Protein Kinase C; Staurosporine | 2002 |
A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Staurosporine | 2004 |
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Enzyme Inhibitors; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Staurosporine | 2004 |
Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Double-Blind Method; Female; Fluorescein Angiography; Humans; Macular Edema; Male; Middle Aged; Protein Kinase C; Retina; Safety; Staurosporine; Tomography, Optical Coherence; Visual Acuity | 2004 |
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Topics: Adult; Aged; Blood Cell Count; Bone Marrow; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Phosphotyrosine; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Staurosporine | 2005 |
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study.
Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Chromatography, High Pressure Liquid; Female; Humans; Isoenzymes; Male; Melanoma; Middle Aged; Protein Kinase C; Staurosporine; Survival Analysis; Treatment Outcome | 2006 |
Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Cohort Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Protein Kinase C; Receptors, Vascular Endothelial Growth Factor; Staurosporine; Time Factors | 2008 |
A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects.
Topics: Administration, Oral; Aged; Algorithms; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Protein Kinase C; Staurosporine; Time Factors | 2008 |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Myelodysplastic Syndromes; Receptor Protein-Tyrosine Kinases; Staurosporine; Treatment Outcome | 2010 |
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers.
Topics: Adolescent; Adult; Antineoplastic Agents; Aza Compounds; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Protein Kinase Inhibitors; Quinolines; Staurosporine; Young Adult | 2012 |
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Remission Induction; Staurosporine; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cohort Studies; Decitabine; Drug Synergism; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Recurrence; Staurosporine | 2013 |
Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.
Topics: Adolescent; Adult; Amino Acid Substitution; Apoptosis; Base Sequence; Benzothiazoles; Cell Proliferation; Cell Transformation, Neoplastic; Core Binding Factor beta Subunit; Cytokines; DNA Mutational Analysis; Exome; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Gene Rearrangement; Humans; Leukemia; Male; Middle Aged; Models, Molecular; Molecular Sequence Data; Mutation; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Staurosporine | 2013 |
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Topics: Adult; Antineoplastic Agents; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Rifampin; Staurosporine; Tandem Mass Spectrometry; Young Adult | 2013 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Female; Humans; Hydrocortisone; Hydroxycholesterols; Male; Middle Aged; Protein Kinase Inhibitors; Rifampin; Staurosporine; Young Adult | 2014 |
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Staurosporine; Young Adult | 2015 |
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Staurosporine; Treatment Outcome | 2015 |
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leukemia, Mast-Cell; Male; Mastocytosis, Systemic; Middle Aged; Multivariate Analysis; Staurosporine; Survival Analysis; Treatment Outcome | 2016 |
Midostaurin in Advanced Systemic Mastocytosis.
Topics: Age of Onset; Antineoplastic Agents; Follow-Up Studies; Humans; Mastocytosis, Systemic; Multivariate Analysis; Staurosporine; Survival Rate | 2016 |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2017 |
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukemia, Mast-Cell; Male; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; Young Adult | 2018 |
Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial.
Topics: Adult; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2018 |
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.
Topics: Adolescent; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Staurosporine; Survival Rate | 2019 |
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Cytarabine; Daunorubicin; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Theoretical; Quality-Adjusted Life Years; Staurosporine; Survival Rate; Treatment Outcome; United States | 2019 |
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study.
Topics: Adult; Aged; Aged, 80 and over; Critical Care; Daunorubicin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Staurosporine; Survival Rate | 2019 |
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2020 |
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Staurosporine; Treatment Outcome | 2020 |
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Staurosporine; Stem Cell Transplantation; Young Adult | 2021 |
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Topics: Adolescent; Adult; Aged; Clonal Evolution; Exome Sequencing; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Staurosporine; Tandem Repeat Sequences | 2021 |
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Biomarkers, Tumor; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Staurosporine; Survival Rate; Young Adult | 2021 |
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Topics: Adolescent; Adult; Aged; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein-Tyrosine Kinases; Staurosporine; Young Adult | 2022 |
Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial.
Topics: Aged; Anthracyclines; Antibiotics, Antineoplastic; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2023 |
324 other study(ies) available for staurosporine and midostaurin
| Article | Year |
|---|---|
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
Topics: Aurora Kinases; Cluster Analysis; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Reproducibility of Results; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Syk Kinase | 2013 |
Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Carbazoles; Cells, Cultured; Cognition Disorders; Drug Discovery; HIV Infections; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinase Kinase 11; Models, Chemical; Molecular Structure; Monocytes; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Pyrroles; tat Gene Products, Human Immunodeficiency Virus; Tumor Necrosis Factor-alpha | 2013 |
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship | 2022 |
Differential effects on neutrophil activation of staurosporin and its protein kinase C-selective derivative cgp 41231.
Topics: Alkaloids; Humans; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Protein Kinase C; Respiratory Burst; Signal Transduction; Staurosporine; Superoxides; Tetradecanoylphorbol Acetate | 1992 |
Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
Topics: 3T3 Cells; Alkaloids; Animals; Antineoplastic Agents; Cells, Cultured; Epidermal Growth Factor; Gene Expression; Genes, fos; Mice; Mice, Inbred BALB C; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase C; Receptors, Platelet-Derived Growth Factor; RNA, Messenger; Signal Transduction; Staurosporine; Stimulation, Chemical; Tetradecanoylphorbol Acetate | 1992 |
Evidence that oocyte maturation induced by an oncogenic ras-p21 protein and insulin is mediated by overlapping yet distinct mechanisms.
Topics: Alanine; Alkaloids; Amino Acid Sequence; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Female; Insulin; Molecular Sequence Data; Oligopeptides; Oncogene Protein p21(ras); Oocytes; Protein Kinase C; Protein Prenylation; Signal Transduction; Staurosporine; Xenopus laevis | 1992 |
Evidence that the ras oncogene-encoded p21 protein induces oocyte maturation via activation of protein kinase C.
Topics: Alanine; Alkaloids; Animals; Enzyme Activation; Humans; Oncogenes; Oogenesis; Protein Kinase C; Proto-Oncogene Proteins p21(ras); Staurosporine; Xenopus laevis | 1992 |
Inhibition or down-regulation of protein kinase C attenuates late phase p70s6k activation induced by epidermal growth factor but not by platelet-derived growth factor or insulin.
Topics: 3T3 Cells; Alkaloids; Animals; Autoradiography; Down-Regulation; Epidermal Growth Factor; Insulin; Mice; Platelet-Derived Growth Factor; Precipitin Tests; Protein Kinase C; Protein Kinases; Ribosomal Protein S6 Kinases; Signal Transduction; Staurosporine; Tetradecanoylphorbol Acetate | 1992 |
Expression of four protein kinase C isoforms in rat fibroblasts. Differential alterations in ras-, src-, and fos-transformed cells.
Topics: Alkaloids; Animals; Blotting, Northern; Cell Line; Cell Line, Transformed; Cell Membrane; Cytosol; Fibroblasts; Genes, ras; Immunoblotting; Isoenzymes; Oncogene Protein pp60(v-src); Oncogene Proteins v-fos; Oncogenes; Protein Kinase C; Rats; Staurosporine; Transcription, Genetic | 1992 |
Inhibition of erythropoietin production by phorbol ester is associated with down-regulation of protein kinase C-alpha isoenzyme in hepatoma cells.
Topics: Alkaloids; Carcinoma, Hepatocellular; Erythropoietin; Humans; Isoenzymes; Kinetics; Liver Neoplasms; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1991 |
On the role of protein kinases in regulating neutrophil actin association with the cytoskeleton.
Topics: Actins; Alkaloids; Chemotactic Factors; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; Humans; Neutrophils; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine; Tetradecanoylphorbol Acetate | 1991 |
A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
Topics: Alkaloids; Animals; Antineoplastic Agents; Brain; Cell Line; ErbB Receptors; Humans; Hydrogen Peroxide; In Vitro Techniques; Mice; Mice, Nude; Monocytes; Phosphorylase Kinase; Phosphorylation; Protein Kinase C; Protein Kinases; Staurosporine; Swine; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1989 |
NMDA receptors increase OH radicals in vivo by using nitric oxide synthase and protein kinase C.
Topics: Alkaloids; Amino Acid Oxidoreductases; Analysis of Variance; Animals; Corpus Striatum; Dizocilpine Maleate; Hydroxyl Radical; Male; N-Methylaspartate; Neurons; Nitric Oxide Synthase; Protein Kinase C; Rats; Receptors, N-Methyl-D-Aspartate; Staurosporine | 1993 |
Modulation of cytokine expression in PB-3c mastocytes by IBMX and PMA.
Topics: 1-Methyl-3-isobutylxanthine; Actins; Alkaloids; Animals; Bone Marrow; Cell Line; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cytokines; Diglycerides; Enzyme Activation; Gene Expression; Genes, ras; Granulocyte-Macrophage Colony-Stimulating Factor; Interleukin-3; Interleukin-6; Mast Cells; Mice; Protein Kinase C; RNA, Messenger; Staurosporine; Tetradecanoylphorbol Acetate; Transfection | 1994 |
Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors.
Topics: Alkaloids; Breast Neoplasms; Cell Membrane; Cytosol; Humans; Immunoblotting; Indoles; Naphthalenes; Phorbol 12,13-Dibutyrate; Polycyclic Compounds; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
Differential effects of PKC inhibitors on gelatinase B and interleukin 6 production in the mouse macrophage.
Topics: Alkaloids; Animals; Biological Assay; Blotting, Northern; Cell Line, Transformed; Collagenases; Gene Expression; Interleukin-6; Macrophages; Matrix Metalloproteinase 9; Mice; Naphthalenes; Nitric Oxide; Polycyclic Compounds; Protein Kinase C; RNA, Messenger; Staurosporine; Tumor Necrosis Factor-alpha | 1995 |
Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro.
Topics: Actins; Adenosine Triphosphatases; Alkaloids; Animals; Carcinoma; Cattle; Cell Line; Cholera Toxin; Colonic Neoplasms; Cytoskeleton; Endothelium, Vascular; Endotoxins; Humans; Ileum; Intercellular Junctions; Intestinal Mucosa; Isoenzymes; Kidney Cortex; Male; Organ Specificity; Permeability; Phosphatidylinositol Diacylglycerol-Lyase; Phosphoric Diester Hydrolases; Protein Kinase C; Pulmonary Artery; Rabbits; Rats; Signal Transduction; Species Specificity; Staurosporine; Swine; Tumor Cells, Cultured; Vibrio cholerae | 1995 |
Differential effect of protein kinase inhibitors (staurosporine and CGP 41,251) on TPA-induced homotypic aggregation and cell surface adhesion antigen expression in human monoblastoid cell line U-937.
Topics: Alkaloids; Cell Aggregation; Humans; Intercellular Adhesion Molecule-1; Lymphoma, Large B-Cell, Diffuse; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1995 |
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Alkaloids; Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Stability; Ethers; Freezing; Humans; Male; Molecular Structure; Protein Kinase C; Rats; Sensitivity and Specificity; Staurosporine | 1995 |
CGP 41251, a novel protein kinase inhibitor with in vitro selectivity for protein kinase C, strongly inhibits immunological activation of human skin mast cells and human basophils.
Topics: Alkaloids; Basophils; Dinoprostone; Female; Histamine Release; Humans; Leukotrienes; Mast Cells; Protein Kinase C; Receptors, IgE; Signal Transduction; Skin; Staurosporine; Tetradecanoylphorbol Acetate | 1993 |
Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Topics: Alkaloids; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line; Dose-Response Relationship, Drug; Humans; Isoenzymes; Lung Neoplasms; Protein Kinase C; Staurosporine; Structure-Activity Relationship; Tumor Cells, Cultured | 1995 |
Protein kinase C regulates calmodulin expression in NRK cells activated to proliferate from quiescence.
Topics: Alkaloids; Animals; Calmodulin; Cattle; Cell Division; Cell Line; Contact Inhibition; Culture Media; Culture Media, Serum-Free; Cyclic AMP-Dependent Protein Kinases; DNA Replication; Epithelial Cells; Epithelium; Fetal Blood; Gene Expression Regulation; Ionomycin; Isoquinolines; Kidney; Protein Kinase C; Rats; RNA, Messenger; Staurosporine; Sulfonamides; Tetradecanoylphorbol Acetate; Transcription, Genetic | 1994 |
Inhibition of protein kinase C results in a switch from a non-motile to a motile phenotype in diverse human lymphocyte populations.
Topics: Alkaloids; B-Lymphocytes; Blotting, Western; Cell Line; Cell Movement; Cells, Cultured; Enzyme Activation; Humans; Indoles; Lymphocytes; Maleimides; Marine Toxins; Oxazoles; Phenotype; Phosphoprotein Phosphatases; Protein Kinase C; Staurosporine; T-Lymphocytes | 1995 |
Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines.
Topics: Alkaloids; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Cycle; Cytarabine; DNA Replication; DNA, Neoplasm; Drug Resistance, Multiple; Drug Synergism; Female; Humans; Leukemia L1210; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred DBA; Neoplasm Proteins; Ovarian Neoplasms; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
Protein kinase C in cultured adult human oligodendrocytes: a potential role for isoform alpha as a mediator of process outgrowth.
Topics: Adult; Alkaloids; Animals; Base Sequence; Benzophenanthridines; Brain; Cells, Cultured; Diterpenes; Female; Humans; Isoenzymes; Molecular Sequence Data; Myelin Sheath; Nerve Tissue Proteins; Oligodendroglia; Phenanthridines; Phorbol Esters; Protein Kinase C; Rats; Rats, Wistar; Staurosporine | 1994 |
The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.
Topics: Alkaloids; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Doxorubicin; Drug Resistance; Gene Expression; Humans; KB Cells; Lymphocytes; Membrane Glycoproteins; Protein Kinase C; Rhodamine 123; Rhodamines; Staurosporine; Tumor Cells, Cultured; Vincristine | 1994 |
Selective effects of the PKC inhibitors Ro 31-8220 and CGP 41,251 on PMN locomotion, cell polarity, and pinocytosis.
Topics: Alkaloids; Amino Acid Sequence; Cell Movement; Cell Polarity; Cell Size; Chemotaxis, Leukocyte; Humans; In Vitro Techniques; Indoles; Molecular Sequence Data; Molecular Weight; Neutrophils; Oligopeptides; Phosphoproteins; Pinocytosis; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate | 1994 |
The protein kinase C inhibitor, CGP 41 251, reverses decreased daunomycin uptake in a human drug-resistant ovarian carcinoma cell line.
Topics: Alkaloids; Daunorubicin; Drug Resistance; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1994 |
Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression.
Topics: Alkaloids; Amino Acid Sequence; Animals; Base Sequence; Caseins; Cell Differentiation; Cell Line; Dexamethasone; Epithelial Cells; Epithelium; Female; Gene Expression Regulation; Insulin; Isoenzymes; Mammary Glands, Animal; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Pregnancy; Prolactin; Protein Kinase C; Protein Kinase C-alpha; Staurosporine; Tetradecanoylphorbol Acetate | 1994 |
Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing.
Topics: Alkaloids; Animals; CD4-Positive T-Lymphocytes; Cell Division; Cytotoxicity, Immunologic; Humans; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Protein Kinase C; Staurosporine; T-Lymphocytes; T-Lymphocytes, Helper-Inducer | 1993 |
[Ca2+]i and protein kinase C in vasopressin-induced prostacyclin and ANP release in rat cardiomyocytes.
Topics: Alkaloids; Animals; Animals, Newborn; Arginine Vasopressin; Atrial Natriuretic Factor; Calcium; Cell Membrane; Cells, Cultured; Cytosol; Dose-Response Relationship, Drug; Epoprostenol; Heart; Kinetics; Myocardium; Nifedipine; Protein Kinase C; Rats; Rats, Wistar; Staurosporine; Time Factors | 1994 |
Oxidative stress causes a protein kinase C-independent increase of paracellular permeability in an in vitro epithelial model.
Topics: Adenosine Triphosphate; Alkaloids; Animals; Cell Line; Dogs; Electrophysiology; Epithelium; Hydrogen Peroxide; In Vitro Techniques; Kidney; Mannitol; Oxidation-Reduction; Permeability; Phorbol 12,13-Dibutyrate; Protein Kinase C; Staurosporine; Superoxides; Time Factors | 1993 |
A role for protein kinase C-alpha in zymosan-stimulated eicosanoid synthesis in mouse peritoneal macrophages.
Topics: Alkaloids; Animals; Arachidonic Acid; Cells, Cultured; Dinoprostone; Eicosanoids; Fatty Acids; Isoenzymes; Kinetics; Leukotriene C4; Macrophages, Peritoneal; Mice; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Zymosan | 1993 |
Transient exposure of human eosinophils to the protein kinase C inhibitors CGP39-360, CGP41-251, and CGP44-800 leads to priming of the respiratory burst induced by opsonized particles.
Topics: Alkaloids; Calcium; Enzyme Inhibitors; Eosinophils; Humans; Opsonin Proteins; Organic Chemicals; Platelet Activating Factor; Protein Kinase C; Respiratory Burst; Staurosporine; Tetradecanoylphorbol Acetate; Zymosan | 1993 |
Guanine nucleotides activate multiple signaling pathways in permeabilized gastric chief cells. Evidence for GTP gamma S-induced calcium-independent pepsinogen secretion.
Topics: Alkaloids; Animals; Bacterial Proteins; Calcium; Carbachol; Cell Membrane Permeability; Cyclic AMP; Cytidine Diphosphate Diglycerides; Gastric Mucosa; GTP-Binding Proteins; Guanine Nucleotides; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Male; Pepsinogens; Phorbol Esters; Phosphorylation; Protein Kinase C; Signal Transduction; Staurosporine; Streptolysins; Type C Phospholipases | 1993 |
Protein kinase C activity is not involved in N-formylmethionyl-leucyl-phenylalanine-induced phospholipase D activation in human neutrophils, but is essential for concomitant NADPH oxidase activation: studies with a staurosporine analogue with improved sel
Topics: Alkaloids; Bucladesine; Enzyme Activation; Humans; In Vitro Techniques; Isoquinolines; Kinetics; N-Formylmethionine Leucyl-Phenylalanine; NADH, NADPH Oxidoreductases; NADPH Oxidases; Neutrophils; Phospholipase D; Protein Kinase C; Staurosporine; Sulfonamides; Superoxides; Tetradecanoylphorbol Acetate | 1993 |
Inhibition of chemotactic peptide-induced development of cell polarity and locomotion by the protein kinase C inhibitor CGP 41 251 in human neutrophils correlates with inhibition of protein phosphorylation.
Topics: Actins; Alkaloids; Cell Movement; Cell Polarity; Cell Size; Humans; In Vitro Techniques; Molecular Weight; Neutrophils; Phosphorylation; Protein Kinase C; Proteins; Staurosporine | 1993 |
Phorbol ester (TPA)-induced differential modulation of cell surface antigens in human pluripotential leukemia (K-562) cell line: effects of protein kinase inhibitors with broad- and PKC selective inhibitory activity.
Topics: Alkaloids; Antigens, CD; CD59 Antigens; Humans; Intercellular Adhesion Molecule-1; Leukemia; Leukocyte Common Antigens; Lymphocyte Function-Associated Antigen-1; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1995 |
Synergistic and selective stimulation of gelatinase B production in macrophages by lipopolysaccharide, trans-retinoic acid and CGP 41251, a protein kinase C regulator.
Topics: Alkaloids; Animals; Base Sequence; Cells, Cultured; Collagenases; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; In Vitro Techniques; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Molecular Sequence Data; Protein Kinase C; Rats; Rats, Inbred F344; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Staurosporine; Tretinoin; Up-Regulation | 1996 |
Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Topics: Alkaloids; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Division; Cell Line; Doxorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Fluorescent Dyes; Humans; Indoles; Maleimides; Protein Kinase C; Rhodamine 123; Rhodamines; Staurosporine; Structure-Activity Relationship; Tumor Cells, Cultured; Vinblastine | 1996 |
Site-related differences in G-protein alpha subunit expression during adipogenesis in vitro: possible key role for Gq/11 alpha in the control of preadipocyte differentiation.
Topics: Adipocytes; Alkaloids; Animals; Cell Differentiation; Cell Division; DNA; Enzyme Inhibitors; Epididymis; Glycerolphosphate Dehydrogenase; GTP-Binding Proteins; Immunoblotting; Male; Protein Kinase C; Rats; Staurosporine; Stem Cells | 1996 |
A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors.
Topics: 3T3 Cells; Alkaloids; Animals; Antigens, Polyomavirus Transforming; Benzamides; Cell Division; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Ethers, Cyclic; Genes, ras; Genes, src; Genetic Vectors; Hydroquinones; Mice; Okadaic Acid; Oncogenes; Phenols; Protein Kinase C; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-raf; Retroviridae; Signal Transduction; Staurosporine; Styrenes; Sulfones; Thiazoles | 1996 |
Effects of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Small Cell; Cell Cycle; Cell Division; DNA, Neoplasm; Enzyme Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Kinase C; Rats; Staurosporine; Transplantation, Heterologous | 1996 |
Modulation by protein kinase C of the enhanced responsiveness to tachykinins in ovalbumin-sensitized guinea pig alveolar macrophages.
Topics: Animals; Bordetella pertussis; Cytochrome c Group; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; Guinea Pigs; Immunization; Macrophages, Alveolar; Male; N-Formylmethionine Leucyl-Phenylalanine; Neurokinin A; Ovalbumin; Peptide Fragments; Protein Kinase C; Receptors, Tachykinin; Staurosporine; Substance P; Superoxides; Tachykinins; Tetradecanoylphorbol Acetate | 1996 |
Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1996 |
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Topics: Animals; Antineoplastic Agents; Biotransformation; Calibration; Chromatography, High Pressure Liquid; Male; Mice; Mice, Inbred Strains; Quality Control; Rats; Reference Standards; Solutions; Staurosporine | 1995 |
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Protein Kinases; Staurosporine; Tumor Cells, Cultured | 1995 |
The role of protein kinase C in nicotinic responses of bovine chromaffin cells.
Topics: Animals; Catecholamines; Cattle; Cells, Cultured; Chromaffin Cells; Enzyme Activation; Enzyme Inhibitors; Phorbol 12,13-Dibutyrate; Protein Kinase C; Receptors, Nicotinic; Recombinant Proteins; Staurosporine; Tyrosine 3-Monooxygenase | 1996 |
Potentiation by thyroxine of interferon-gamma-induced antiviral state requires PKA and PKC activities.
Topics: Animals; Calmodulin; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Estrenes; HeLa Cells; Humans; Indoles; Interferon-gamma; L Cells; Mice; Protein Kinase C; Pyrroles; Pyrrolidinones; Rhabdoviridae Infections; Staurosporine; Sulfonamides; Tetradecanoylphorbol Acetate; Thyroxine; Time Factors; Vesicular stomatitis Indiana virus; Viral Interference | 1996 |
Phosphorylation of myeloid-related proteins MRP-14 and MRP-8 during human neutrophil activation.
Topics: Antigens, Differentiation; Arachidonic Acid; Calcimycin; Calcium; Calcium-Binding Proteins; Calgranulin A; Calgranulin B; Cell Membrane; Cytochalasin B; Cytoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Immunoblotting; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Phosphorylation; Staurosporine; Tetradecanoylphorbol Acetate | 1996 |
Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
Topics: Animals; Antineoplastic Agents; Diet; Female; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway.
Topics: Blood Physiological Phenomena; Cell Division; Enzyme Activation; Genistein; Glioma; Humans; Isoflavones; Protein Kinase C; Protein-Tyrosine Kinases; Signal Transduction; Staurosporine; Tumor Cells, Cultured | 1996 |
Stimulation of 1-(beta-D-arabinofuranosyl)cytosine (AraC)-induced apoptosis in the multidrug resistant human promyelocytic leukemia cell lines with protein kinase inhibitors.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; DNA, Neoplasm; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Genistein; HL-60 Cells; Humans; Isoflavones; Protein Kinase C; Staurosporine | 1996 |
Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Mice; Phosphorylation; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1997 |
The promoting effects of bFGF and astrocyte extracellular matrix on process outgrowth by adult human oligodendrocytes are mediated by protein kinase C.
Topics: Astrocytes; Cells, Cultured; Enzyme Inhibitors; Extracellular Matrix; Fibroblast Growth Factor 2; Humans; Naphthalenes; Oligodendroglia; Phorbol 12,13-Dibutyrate; Protein Kinase C; Staurosporine | 1997 |
Protein kinase inhibitor-induced alterations of drug uptake, cell cycle and surface antigen expression in human multidrug-resistant (Pgp and MRP) promyelocytic leukemia HL-60 cells.
Topics: Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; CD59 Antigens; Cell Cycle; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Genistein; Histocompatibility Antigens Class I; HL-60 Cells; HLA-DR Antigens; Humans; Intercellular Adhesion Molecule-1; Isoflavones; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Rhodamine 123; Rhodamines; Staurosporine; Vincristine | 1997 |
Cellular relocalisation of protein kinase C-theta caused by staurosporine and some of its analogues.
Topics: Alkaloids; Antineoplastic Agents; Blotting, Western; Cell Membrane; Cell Nucleus; Cytosol; Enzyme Inhibitors; Fluorescent Antibody Technique, Indirect; Humans; Indoles; Isoenzymes; Maleimides; Microscopy, Confocal; Models, Chemical; Protein Kinase C; Protein Kinase C-theta; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Zinc Fingers | 1997 |
CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells.
Topics: Astrocytoma; Calcium-Calmodulin-Dependent Protein Kinases; Carbazoles; Cyclic AMP Response Element-Binding Protein; Enzyme Activation; Enzyme Inhibitors; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-fos; Staurosporine; Substance P; Tamoxifen; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Tyrosine | 1997 |
Antisense oligodeoxynucleotide to PKC-delta blocks alpha 1-adrenergic activation of Na-K-2Cl cotransport.
Topics: Acetophenones; Base Sequence; Benzopyrans; Biological Transport; Bumetanide; Calcium-Calmodulin-Dependent Protein Kinases; Carrier Proteins; Cells, Cultured; Chlorides; Enzyme Inhibitors; Humans; Isoenzymes; Kinetics; Methoxamine; Mucous Membrane; Naphthalenes; Nystatin; Oligonucleotides, Antisense; Protein Kinase C; Protein Kinase C-delta; Receptors, Adrenergic, alpha-1; RNA, Messenger; Sodium-Potassium-Chloride Symporters; Staurosporine; Trachea; Transcription, Genetic | 1997 |
Role of cAMP and calcium influx in endothelin-1-induced ANP release in rat cardiomyocytes.
Topics: Alkaloids; Animals; Animals, Newborn; Atrial Natriuretic Factor; Benzophenanthridines; Calcium; Cells, Cultured; Cyclic AMP; Cyclooxygenase Inhibitors; Egtazic Acid; Endothelin-1; Enzyme Inhibitors; Epoprostenol; Heart; Heart Ventricles; Kinetics; Myocardium; Naphthalenes; Nifedipine; Phenanthridines; Protein Kinase C; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Staurosporine; Thionucleotides | 1997 |
Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
Topics: Adenocarcinoma; Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1997 |
Analysis of drug/plasma protein interactions by means of asymmetrical flow field-flow fractionation.
Topics: Adsorption; alpha-Macroglobulins; Chemical Fractionation; Chromatography; Enzyme Inhibitors; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Membranes, Artificial; Protein Kinase C; Reference Standards; Serum Albumin; Spectrometry, Fluorescence; Staurosporine | 1997 |
Protein kinase C induced changes in erythrocyte Na+/H+ exchange and cytosolic free calcium in humans.
Topics: Calcium; Calpain; Carcinogens; Cytosol; Enzyme Inhibitors; Erythrocytes; Humans; Protein Kinase C; Sodium; Sodium-Hydrogen Exchangers; Staurosporine; Tetradecanoylphorbol Acetate | 1998 |
Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700.
Topics: Antineoplastic Agents; Drug Resistance, Multiple; Gene Expression Regulation; Genes, MDR; HeLa Cells; Humans; Rhodamines; Staurosporine; Transfection | 1998 |
Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Topics: Aged; Animals; Antineoplastic Agents; Astrocytes; Bromodeoxyuridine; Cell Cycle; Enzyme Inhibitors; Female; Glioblastoma; Humans; Isoenzymes; Male; Mice; Mice, Inbred BALB C; Middle Aged; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1996 |
Influence of probes for calcium-calmodulin and protein kinase C signalling on the plasma membrane Ca2+-ATPase activity of rat synaptosomes and leukocyte membranes.
Topics: Animals; Calcium; Calcium Channel Blockers; Calcium-Transporting ATPases; Calmodulin; Cell Membrane; Enzyme Inhibitors; Gallic Acid; Imidazoles; Leukocytes; Male; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phosphorylcholine; Protein Kinase C; Quercetin; Rats; Rats, Wistar; Signal Transduction; Sphingosine; Staurosporine; Synaptosomes | 1998 |
A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells.
Topics: Antineoplastic Agents; Astrocytoma; Carbazoles; Cell Division; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ets-Domain Protein Elk-1; Humans; Indoles; Potassium Channels; Protein Kinase C; Proto-Oncogene Proteins; Staurosporine; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 1999 |
Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell-Free System; Cyclin B; Cyclin B1; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mitosis; Nocodazole; Phosphoprotein Phosphatases; Phosphorylation; Proteins; Skin Neoplasms; Staurosporine; Tumor Cells, Cultured; Tyrosine | 1999 |
Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.
Topics: Administration, Oral; Animals; Choroidal Neovascularization; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Male; Mice; Mice, Inbred C57BL; Protein Kinase C; Protein-Tyrosine Kinases; Retina; Retinal Neovascularization; Retinal Vessels; Staurosporine | 1999 |
Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Female; Mice; Mice, Inbred BALB C; Protein Kinase C; Staurosporine | 1999 |
Ectopic expression of protein kinase CbetaII, -delta, and -epsilon, but not -betaI or -zeta, provide for insulin stimulation of glucose uptake in NIH-3T3 cells.
Topics: 3-O-Methylglucose; 3T3 Cells; Animals; Biological Transport, Active; Deoxyglucose; Diglycerides; Enzyme Inhibitors; Gene Expression; Glucose; Glucose Transporter Type 1; Insulin; Isoenzymes; Mice; Monosaccharide Transport Proteins; Protein Kinase C; Receptor, Insulin; Recombinant Proteins; Signal Transduction; Staurosporine | 1999 |
Structure-activity relationship of staurosporine analogs in regulating expression of endothelial nitric-oxide synthase gene.
Topics: Alkaloids; Animals; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP-Dependent Protein Kinases; Drug Interactions; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Promoter Regions, Genetic; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Rats; RNA, Messenger; Staurosporine; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2000 |
PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Topics: Angiogenesis Inhibitors; Animals; Blood Proteins; Cell Cycle; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Mice; Neoplasms; Protein Binding; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 2000 |
Differential requirement for classic and novel PKC isoforms in respiratory burst and phagocytosis in RAW 264.7 cells.
Topics: Animals; Biological Transport; Calcium; Cell Line; Cell Membrane; Diglycerides; Enzyme Inhibitors; Green Fluorescent Proteins; Intracellular Membranes; Isoenzymes; Luminescent Proteins; Macrophages; Mice; Naphthalenes; Phagocytosis; Phagosomes; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Protein Kinase C-delta; Protein Kinase C-epsilon; Respiratory Burst; Staurosporine | 2000 |
Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway.
Topics: Animals; Apoptosis; Caspase 9; Caspases; Cytochrome c Group; Enzyme Inhibitors; Humans; Neoplasms; Protein Kinase C; Radiation Tolerance; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Genotype; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Protein Kinase C; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2001 |
CGP 41251, a new potential anticancer drug, improves contractility of rat isolated cardiac muscle subjected to hypoxia.
Topics: Animals; Antineoplastic Agents; Endocardium; Female; Hypoxia; Male; Myocardial Contraction; Myocardial Reperfusion; Papillary Muscles; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Staurosporine | 2001 |
In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cisplatin; Cyclosporins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Inhibitory Concentration 50; Piperidines; Pyridines; Quinolines; Razoxane; Rhabdomyosarcoma; RNA, Neoplasm; Staurosporine; Time Factors; Tumor Cells, Cultured; Vincristine | 2001 |
The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
Topics: Animals; Cell Line, Transformed; Cell Transformation, Neoplastic; Chromones; Down-Regulation; Enzyme Inhibitors; Genes, ras; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Staurosporine; Tumor Cells, Cultured | 2001 |
Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Topics: 2-Chloroadenosine; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium Channel Blockers; Chlorambucil; Deoxyadenosines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Palatine Tonsil; Protein Kinase C; Staurosporine; Tumor Cells, Cultured; Verapamil; Vidarabine | 2002 |
A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti- ras peptide.
Topics: Antineoplastic Agents; Carcinoma, Acinar Cell; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Oncogene Protein p21(ras); Pancreatic Neoplasms; Peptide Fragments; Phenotype; Protein Binding; Protein Kinase C; Signal Transduction; Staurosporine | 2002 |
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Immunoblotting; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Protein Kinase C; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Staurosporine; Transfection; Tumor Cells, Cultured | 2002 |
Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells.
Topics: Animals; Cell Division; Enzyme Inhibitors; Female; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Transplantation; Platelet Aggregation; Protein Kinase C; Rabbits; Staurosporine; Tumor Cells, Cultured | 2003 |
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Topics: Animals; Annexin A5; Antineoplastic Agents; Child, Preschool; DNA-Binding Proteins; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Histone-Lysine N-Methyltransferase; Humans; In Situ Hybridization, Fluorescence; Interleukin-3; Mice; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogenes; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Transcription Factors; Transfection; Tumor Cells, Cultured | 2003 |
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Topics: Acute Disease; Amino Acid Substitution; Animals; Cell Division; Cell Line; Codon; DNA-Binding Proteins; Drug Resistance; Enzyme Activation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cells; Humans; Indoles; Leukemia, Myeloid; Membrane Proteins; Mice; Milk Proteins; Mutagenesis, Insertional; Mutation, Missense; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Proteins; Sequence Deletion; STAT5 Transcription Factor; Staurosporine; Structure-Activity Relationship; Trans-Activators; Transfection; Tyrphostins | 2003 |
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Marrow; Bone Marrow Transplantation; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Fusion Proteins, bcr-abl; Genetic Vectors; Humans; Imatinib Mesylate; Immunophenotyping; Mice; Models, Genetic; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Precipitin Tests; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Retroviridae; Spleen; Staurosporine; Time Factors | 2003 |
The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies.
Topics: Angiogenesis Inhibitors; Animals; Cell Division; Enzyme Inhibitors; Epiretinal Membrane; Glial Fibrillary Acidic Protein; Immunoenzyme Techniques; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phthalazines; Platelet-Derived Growth Factor; Protein Kinase C; Proto-Oncogene Proteins c-sis; Pyridines; Retina; Retinal Detachment; Staurosporine | 2003 |
Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model.
Topics: Animals; Biocompatible Materials; Biological Availability; Bruch Membrane; Choroid; Choroidal Neovascularization; Disease Models, Animal; Drug Carriers; Female; Injections; Lactic Acid; Laser Coagulation; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Protein Kinase C; Retina; Staurosporine; Swine; Vitreous Body | 2003 |
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Transformed; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Genistein; Humans; Indoles; Leukemia, Myeloid; MAP Kinase Signaling System; Milk Proteins; Mutagenesis; Phenotype; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; STAT5 Transcription Factor; Staurosporine; Trans-Activators; Tyrphostins | 2004 |
Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?
Topics: Cell Survival; Combined Modality Therapy; Down-Regulation; Endothelial Cells; Enzyme Inhibitors; ErbB Receptors; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phthalazines; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Pyrroles; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Staurosporine | 2004 |
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sirolimus; Staurosporine | 2004 |
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Cysteine Endopeptidases; DNA-Binding Proteins; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; G1 Phase; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multienzyme Complexes; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Rifabutin; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Trans-Activators; Ubiquitin | 2004 |
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Topics: Adult; Aged; Aged, 80 and over; Cell Division; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Humans; Hydrogen Bonding; Interleukin-3; Leukemia, Myeloid, Acute; Male; Middle Aged; Models, Molecular; Mutation; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Staurosporine | 2004 |
Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Enzyme Inhibitors; Free Radicals; Hypoglycemic Agents; Male; Multienzyme Complexes; NADH, NADPH Oxidoreductases; NADPH Oxidases; Obesity; Oxidative Stress; Pioglitazone; Rats; Rats, Wistar; Rats, Zucker; Staurosporine; Thiazolidinediones; Thinness | 2004 |
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; DNA; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Exons; Flow Cytometry; fms-Like Tyrosine Kinase 3; G1 Phase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Proteasome Endopeptidase Complex; Protein Binding; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Time Factors; Trans-Activators | 2004 |
PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts.
Topics: Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cells, Cultured; Enzyme Inhibitors; Female; Fibroblasts; Humans; Keloid; Staurosporine | 2004 |
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Topics: Acute Disease; Amino Acid Sequence; Animals; Drug Resistance, Neoplasm; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid; Mice; Models, Molecular; Molecular Sequence Data; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Staurosporine; Structure-Activity Relationship | 2004 |
PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.
Topics: Animals; Cell Line; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Disease Models, Animal; Female; Genetic Variation; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Middle Aged; Myeloproliferative Disorders; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Fibroblast Growth Factor; Staurosporine; Transformation, Genetic; Translocation, Genetic; Zinc Fingers | 2004 |
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine | 2005 |
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Topics: Acute Disease; Animals; Apoptosis; Cell Line; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Milk Proteins; Muridae; Mutagenesis, Site-Directed; Myeloid Cells; Phosphorylation; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Tandem Repeat Sequences; Trans-Activators; Transcription Factors | 2005 |
PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Damage; DNA, Neoplasm; Enzyme Inhibitors; Humans; Intracellular Membranes; Kinetics; Lung Neoplasms; Membrane Potentials; Mitochondria; Protein Kinase Inhibitors; Staurosporine | 2005 |
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
Topics: Animals; B-Lymphocytes; Benzamides; Cell Line; DNA-Binding Proteins; Drug Resistance; Enzyme Activation; Enzyme Inhibitors; Humans; Imatinib Mesylate; Mice; Milk Proteins; Mutation; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; STAT3 Transcription Factor; STAT5 Transcription Factor; Staurosporine; Trans-Activators | 2005 |
[New targets for molecular therapy of acute leukemia: a "single-hit" or "multiple-hit" strategy against signaling pathway].
Topics: Acute Disease; Antineoplastic Agents; Carbazoles; Furans; Humans; Indoles; Leukemia; Leukemia, Myeloid, Acute; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Quinolones; ras Proteins; Staurosporine | 2005 |
Midostaurin upregulates eNOS gene expression and preserves eNOS function in the microcirculation of the mouse.
Topics: Animals; Aorta; Apolipoproteins E; Enzyme Induction; Male; Mice; Mice, Knockout; Microcirculation; Nitrates; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; Reactive Oxygen Species; RNA, Messenger; Staurosporine; Vasodilation | 2005 |
Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production.
Topics: Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Calcium; Humans; Lymphocyte Activation; Protein Kinase C; Protein Kinase Inhibitors; Receptors, Interleukin-2; Receptors, Transferrin; Staurosporine; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2005 |
The hypereosinophilic syndrome: idiopathic or not, that is the question.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Chronic Disease; Clone Cells; Diagnosis, Differential; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lymphoproliferative Disorders; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; T-Lymphocyte Subsets | 2005 |
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Line, Tumor; DNA; DNA Mutational Analysis; DNA Primers; Dose-Response Relationship, Drug; Drug Resistance; Enzyme Inhibitors; Gene Duplication; Gene Rearrangement; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Infant; Infant, Newborn; Ligands; Mutation; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sequence Analysis, DNA; Staurosporine; Tetrazolium Salts; Thiazoles | 2005 |
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Topics: Aspartic Acid; Cell Proliferation; Cells, Cultured; Female; Humans; Immunophenotyping; Leukemia, Mast-Cell; Middle Aged; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Staurosporine | 2005 |
FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia.
Topics: Adult; Blotting, Western; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; DNA, Complementary; fms-Like Tyrosine Kinase 3; Humans; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase C; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Signal Transduction; Staurosporine; Translocation, Genetic | 2005 |
N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Caspase 3; Cell Line, Tumor; Enzyme Inhibitors; Flow Cytometry; Humans; Interleukin-6; Membrane Potentials; Mitochondria; Multiple Myeloma; Phosphorylation; Proto-Oncogene Proteins c-akt; Staurosporine | 2005 |
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
Topics: Animals; Bone Marrow Transplantation; Cell Line, Tumor; Disease Models, Animal; Growth Inhibitors; Hematologic Neoplasms; Lymphoma, B-Cell; Mice; Multiple Myeloma; Myeloproliferative Disorders; Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 3; Recombinant Fusion Proteins; Staurosporine; Thanatophoric Dysplasia; Transfection | 2005 |
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.
Topics: Animals; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia; Lymphoma; Mice; Mice, Transgenic; Mutation; Myeloproliferative Disorders; Phenotype; Promoter Regions, Genetic; Protein Kinase C; Staurosporine | 2005 |
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Topics: Acute Disease; Drug Resistance, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid; Mutation, Missense; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Recurrence; Staurosporine | 2006 |
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Topics: Anti-Bacterial Agents; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; CD2 Antigens; Cell Proliferation; Cells, Cultured; Cladribine; Down-Regulation; Doxycycline; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; Female; Humans; Imatinib Mesylate; Immunophenotyping; In Vitro Techniques; Leukemia, Mast-Cell; Middle Aged; Mutation; Phosphorylation; Piperazines; Platelet Membrane Glycoproteins; Protein Kinase C; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tetraspanin 30 | 2006 |
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Topics: Amino Acid Sequence; Animals; Apoptosis; Base Sequence; Cell Line; DNA, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; In Vitro Techniques; Interleukin-3; Leukemia, Myeloid, Acute; Mice; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Phosphorylation; Point Mutation; Protein Structure, Tertiary; Recombinant Proteins; STAT5 Transcription Factor; Staurosporine; Tyrosine | 2006 |
Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Chromones; Enzyme Inhibitors; Etoposide; Flavonoids; Flow Cytometry; Humans; Indoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mitosis; Morpholines; Nocodazole; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Staurosporine; Wortmannin | 2006 |
[The present status of, and problems with the development of FLT3 kinase inhibitors].
Topics: Adult; Cell Cycle Proteins; Chaperonins; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Mutation; Piperazines; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Staurosporine | 2006 |
Reversal of endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats.
Topics: Animals; Endothelium, Vascular; Enzyme Inhibitors; Hypertension; Male; Nitric Oxide Synthase; Protein Kinase C; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Staurosporine; Up-Regulation | 2006 |
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Topics: Antineoplastic Agents; Carbazoles; Case-Control Studies; Cell Line; Cell Survival; Cells, Cultured; Drug Screening Assays, Antitumor; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Inhibitory Concentration 50; Leukemia; Pharmacokinetics; Plasma; Staurosporine | 2006 |
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.
Topics: Acute Disease; Adolescent; Adult; Aged; Apoptosis; Blast Crisis; Carbazoles; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid; Male; Middle Aged; Mutation; Protein Kinase C; Protein-Tyrosine Kinases; Signal Transduction; Staurosporine; Tumor Cells, Cultured | 2006 |
PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.
Topics: Apoptosis; Cell Line, Tumor; Gene Expression Regulation; Humans; JNK Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-kappa B; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-fos; Staurosporine; Tumor Cells, Cultured | 2007 |
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
Topics: DNA Repair; Drug Resistance, Neoplasm; Etoposide; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Rad51 Recombinase; RNA, Small Interfering; STAT5 Transcription Factor; Staurosporine; Tandem Repeat Sequences | 2006 |
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Male; Mice; Mice, Nude; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Staurosporine; Tyrosine; Xenograft Model Antitumor Assays | 2006 |
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line; DNA Primers; Drug Synergism; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligoribonucleotides, Antisense; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Staurosporine; Transfection | 2007 |
Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cytokines; Drug Therapy, Combination; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Protein Kinase C; Spleen; Staurosporine; Xenograft Model Antitumor Assays | 2006 |
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytarabine; Doxorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia; Methotrexate; Mitoxantrone; Mutation; Protein Kinase C; Staurosporine | 2007 |
Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Exons; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoprecipitation; Mice; Mutation; Myeloid Progenitor Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine | 2007 |
PKC412 (CGP41251) modulates the proliferation and lipopolysaccharide-induced inflammatory responses of RAW 264.7 macrophages.
Topics: Animals; Apoptosis; Cell Line; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; Drug Combinations; Immunologic Factors; Lipopolysaccharides; Macrophages; Mice; Staurosporine | 2007 |
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Mice; Mitochondrial Proteins; Mutant Proteins; Oligopeptides; Staurosporine; Stromal Cells | 2007 |
PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Flow Cytometry; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Microcirculation; Pancreatic Neoplasms; Point Mutation; Polymerase Chain Reaction; Protein Kinase C; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; Signal Transduction; Staurosporine; Tandem Repeat Sequences; Tumor Cells, Cultured | 2007 |
Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.
Topics: Animals; Cell Line; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; STAT5 Transcription Factor; Staurosporine; Transduction, Genetic | 2007 |
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
Topics: Active Transport, Cell Nucleus; Acute Disease; Animals; beta Catenin; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Interleukin-3; Leukemia, Myeloid; Membrane Proteins; Mice; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Protein Processing, Post-Translational; Recombinant Proteins; RNA, Small Interfering; Staurosporine; Transcription, Genetic; Tyrphostins | 2007 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2008 |
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dasatinib; Drug Synergism; Humans; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2007 |
Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.
Topics: Enzyme Activation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Juvenile; RNA, Messenger; Staurosporine | 2007 |
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
Topics: Adult; Alleles; Animals; Cell Proliferation; DNA Mutational Analysis; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Monocytic, Acute; Mice; Mutant Proteins; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Secondary; Signal Transduction; Staurosporine | 2007 |
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.
Topics: Apoptosis; bcl-Associated Death Protein; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; Serine; Signal Transduction; Staurosporine; U937 Cells | 2008 |
Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities.
Topics: Animals; Antineoplastic Agents; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paired Box Transcription Factors; PAX3 Transcription Factor; Phosphorylation; Rhabdomyosarcoma; RNA Processing, Post-Transcriptional; Staurosporine | 2008 |
Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Male; Oncostatin M; Osteosarcoma; Rats; Rats, Sprague-Dawley; Staurosporine | 2008 |
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbanilides; Cell Line; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine | 2008 |
Peptide biosensors for the electrochemical measurement of protein kinase activity.
Topics: Adenosine Triphosphate; Benzimidazoles; Biosensing Techniques; Bone Neoplasms; Casein Kinase II; Catalysis; Electrochemistry; Ferrous Compounds; fms-Like Tyrosine Kinase 3; Humans; Kinetics; Metallocenes; Mutation; Osteosarcoma; Oxidation-Reduction; Peptide Fragments; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Receptor, ErbB-2; Staurosporine; Triazoles; Tumor Cells, Cultured | 2008 |
BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Forkhead Box Protein O3; Forkhead Transcription Factors; Hematopoietic Stem Cells; Humans; Immunoprecipitation; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mutation; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Staurosporine; Transduction, Genetic; Tyrphostins | 2009 |
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phenotype; Protein Array Analysis; Signal Transduction; Staurosporine; Substrate Specificity; Up-Regulation | 2009 |
Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Staurosporine; Tandem Repeat Sequences; Transfection; Tumor Cells, Cultured | 2009 |
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin | 2008 |
New agents for the treatment of AML recent study findings.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide | 2008 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
Topics: Animals; Benzenesulfonates; Cell Line; Drug Resistance; fms-Like Tyrosine Kinase 3; Indoles; Mice; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Receptors, Platelet-Derived Growth Factor; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2009 |
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles | 2009 |
Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; K562 Cells; Leukemia; Megakaryocytes; Protein Kinase Inhibitors; Receptors, Thrombopoietin; Signal Transduction; Staurosporine; Time Factors; Up-Regulation | 2009 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mast Cells; Mastocytosis, Systemic; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Staurosporine; Transfection | 2009 |
Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells.
Topics: Antigens, CD; Basophils; Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Humans; Immunoglobulin E; Inflammation Mediators; Mast Cells; Mastocytosis, Systemic; Phosphoric Diester Hydrolases; Platelet Membrane Glycoproteins; Proto-Oncogene Proteins c-kit; Pyrophosphatases; Staurosporine; Tetraspanin 30; Up-Regulation | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Topics: Cell Line, Tumor; Chromosomes, Human, Pair 13; Clinical Trials as Topic; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mutation; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Staurosporine | 2010 |
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles | 2010 |
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Early Growth Response Protein 1; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Genotype; Histone Deacetylase Inhibitors; Humans; Mice; Neoplasms; Paired Box Transcription Factors; Rhabdomyosarcoma, Alveolar; Staurosporine; Transcriptional Activation; Valproic Acid; Xenograft Model Antitumor Assays | 2010 |
Interactive medical case. A rash hypothesis.
Topics: Acetates; Adult; Anti-Inflammatory Agents; Cromolyn Sodium; Cyclopropanes; Diarrhea; Drug Therapy, Combination; Enzyme Inhibitors; Exanthema; Female; Flushing; Histamine H2 Antagonists; Humans; Leukotriene Antagonists; Mastocytosis, Systemic; Prednisone; Protein-Tyrosine Kinases; Quinolines; Ranitidine; Staurosporine; Sulfides; Tryptases; Vomiting | 2010 |
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cats; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Histamine H1 Antagonists, Non-Sedating; Humans; Inhibitory Concentration 50; Loratadine; Mastocytoma; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Terfenadine; Thiazoles; Tumor Cells, Cultured | 2010 |
Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Caspase 3; Cell Growth Processes; Cell Survival; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mutation; Oleanolic Acid; Phosphorylation; Signal Transduction; Staurosporine | 2010 |
Midostaurin (PKC412) modulates differentiation and maturation of human myeloid dendritic cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Biomarkers; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dendritic Cells; Endocytosis; Humans; Lipopolysaccharides; Protein Kinase C; Staurosporine; Transport Vesicles | 2010 |
Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Topics: Animals; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Staurosporine | 2010 |
Effects of the protein kinase inhibitor PKC412 on gene expression and link to physiological effects in zebrafish Danio rerio eleuthero-embryos.
Topics: Animals; Antineoplastic Agents; Apoptosis; Circadian Rhythm; Comet Assay; Embryo, Nonmammalian; Gene Expression; Gene Expression Profiling; In Situ Nick-End Labeling; Motor Activity; Neovascularization, Physiologic; Protein Kinase Inhibitors; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Zebrafish | 2011 |
Critical role for hyperpolarization-activated cyclic nucleotide-gated channel 2 in the AIF-mediated apoptosis.
Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Calcium; Calpain; Caspases; Cell Line; Cell Line, Tumor; Cells, Cultured; Enzyme Inhibitors; Gene Expression; HEK293 Cells; Humans; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Ion Channels; Neurons; Phosphorylation; Potassium Channels; Protein Kinase C; Rats; Rats, Sprague-Dawley; Staurosporine | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferation.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Cells, Cultured; Gene Expression Regulation; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; Microphthalmia-Associated Transcription Factor; MicroRNAs; NIH 3T3 Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Staurosporine | 2011 |
Up-regulation of homeodomain genes, DLX1 and DLX2, by FLT3 signaling.
Topics: Antigens, Surface; Cell Line, Tumor; Cell Nucleus; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Gene Silencing; Homeodomain Proteins; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Smad2 Protein; Staurosporine; Transcription Factors; Transforming Growth Factor beta; Up-Regulation | 2011 |
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles | 2011 |
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aniline Compounds; Cell Line, Tumor; Dasatinib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mast Cells; Mastocytosis, Systemic; Mutation; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Staurosporine; Thiazoles; Tumor Cells, Cultured | 2011 |
FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
Topics: Antineoplastic Agents; Benzothiazoles; Carbazoles; Clinical Trials as Topic; Cytokines; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib; Tandem Repeat Sequences | 2011 |
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Stability; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Half-Life; Humans; Leukemia, Myeloid, Acute; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; Staurosporine; Thiazoles; Tyrosine; Up-Regulation | 2011 |
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.
Topics: Animals; Blotting, Western; Bone Marrow Transplantation; Cell Survival; Cells, Cultured; Disease Progression; Female; Flow Cytometry; Green Fluorescent Proteins; Humans; Leukemia; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinases; Mutation; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Signal Transduction; STAT3 Transcription Factor; STAT5 Transcription Factor; Staurosporine | 2012 |
Tetracyclines convert the osteoclastic-differentiation pathway of progenitor cells to produce dendritic cell-like cells.
Topics: Animals; B7-2 Antigen; Bone Resorption; CD11c Antigen; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dendritic Cells; Doxycycline; Enzyme Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Minocycline; Mitogen-Activated Protein Kinases; NF-kappa B; Osteoclasts; Phagocytosis; Proto-Oncogene Proteins c-fos; RANK Ligand; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Stem Cells | 2012 |
Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caveolin 1; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Mice; Mice, Inbred NOD; Nuclear Proteins; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; Random Allocation; RNA Interference; RNA-Binding Protein EWS; RNA, Small Interfering; Sarcoma, Ewing; Small Molecule Libraries; Staurosporine; Transcription Factors; Xenograft Model Antitumor Assays; Zebrafish Proteins | 2012 |
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; STAT5 Transcription Factor; Staurosporine; Stromal Cells; Thiazoles | 2012 |
Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Synergism; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Paclitaxel; Protein Kinase C; Signal Transduction; Staurosporine; Time Factors | 2012 |
H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.
Topics: Benzoxazoles; Cell Line, Tumor; Endoplasmic Reticulum; Fluorescent Dyes; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hydrogen Peroxide; Imidazoles; Leukemia, Myeloid, Acute; Mitochondria; Mutation; NADPH Oxidases; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-pim-1; Pyrroles; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Triazoles | 2012 |
Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Topics: Apoptosis; Benzothiazoles; Caspases; Cell Line; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Stability; Proteolysis; Signal Transduction; STAT5 Transcription Factor; Staurosporine | 2012 |
FLT3-driven redox-modulation of Ezrin regulates leukaemic cell migration.
Topics: Cell Line; Cell Movement; Cytoskeletal Proteins; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myelomonocytic, Acute; NADPH Oxidases; Onium Compounds; Oxidation-Reduction; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Staurosporine; Transfection | 2013 |
Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.
Topics: Animals; Antiviral Agents; Butadienes; Carbazoles; Cell Line, Tumor; Cell Survival; Genome, Viral; Herpesvirus 4, Human; Humans; Indole Alkaloids; MAP Kinase Signaling System; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; NF-kappa B; Nitriles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sf9 Cells; Staurosporine; Viral Proteins; Virus Replication | 2012 |
ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Hematopoiesis; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Staurosporine | 2012 |
Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Topics: Acrylamides; Amino Acid Substitution; Animals; Area Under Curve; Base Sequence; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; RNA Interference; Staurosporine; Xenograft Model Antitumor Assays | 2013 |
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; Ephrin-B3; Extracellular Signal-Regulated MAP Kinases; G2 Phase Cell Cycle Checkpoints; Humans; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Radiation, Ionizing; RNA Interference; RNA, Small Interfering; Signal Transduction; Staurosporine; Up-Regulation | 2013 |
Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation.
Topics: Acute Disease; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Indoles; K562 Cells; Leukemia, Myeloid; Lysophosphatidylcholines; Lysophospholipids; Mutation; Oligonucleotide Array Sequence Analysis; Phosphoric Diester Hydrolases; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Staurosporine; Tandem Repeat Sequences | 2013 |
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Topics: Antineoplastic Agents; Benzothiazoles; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Phenylurea Compounds; Pyrroles; Staurosporine; Sunitinib | 2013 |
Dual inhibition of classical protein kinase C-α and protein kinase C-β isoforms protects against experimental murine diabetic nephropathy.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Isoenzymes; Kidney; Male; Mice; Mice, Knockout; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-alpha; Staurosporine | 2013 |
Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.
Topics: Apoptosis; Benzothiazoles; Bone Marrow Cells; Cell Communication; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Stromal Cells | 2013 |
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Female; Growth Inhibitors; Humans; Imidazoles; Male; Mastocytosis, Systemic; Middle Aged; Proto-Oncogene Proteins c-kit; Pyridazines; Staurosporine | 2013 |
A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF.
Topics: AMP-Activated Protein Kinases; Blotting, Western; Cell Line; Cell Survival; Chromatography, Liquid; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Indoles; Mass Spectrometry; Melanocytes; Melanoma; Microphthalmia-Associated Transcription Factor; Oncogenes; Pyrroles; RNA Interference; RNA, Small Interfering; Staurosporine; Sunitinib; Transfection | 2014 |
KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
Topics: Adult; Aged; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Mutation; Protein Isoforms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Staurosporine | 2013 |
Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells.
Topics: Antineoplastic Agents; Catechin; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression; Gene Expression Regulation, Leukemic; HSP90 Heat-Shock Proteins; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitogen-Activated Protein Kinases; Mutagenesis, Insertional; Phosphorylation; Point Mutation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Staurosporine | 2013 |
Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
Topics: Animals; Bone Marrow; Bone Marrow Transplantation; Cells, Cultured; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Histone-Lysine N-Methyltransferase; Leukemia, Myeloid; Mice; Mice, Knockout; Myeloid Progenitor Cells; Myeloid-Lymphoid Leukemia Protein; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Signal Transduction; Staurosporine | 2013 |
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
Topics: Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Furans; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Quinazolines; Staurosporine | 2013 |
Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
Topics: Chromatography, Liquid; Drug Monitoring; Drug Stability; Humans; Linear Models; Mastocytosis, Systemic; Reproducibility of Results; Sensitivity and Specificity; Staurosporine; Tandem Mass Spectrometry | 2014 |
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.
Topics: Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Phenylurea Compounds; Staurosporine; T-Lymphocytes | 2014 |
Mast cell leukemia: an extremely rare disease.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Mast-Cell; Male; Piperazines; Pyrimidines; Staurosporine | 2014 |
Mast cell leukemia with prolonged survival on PKC412/midostaurin.
Topics: Aged; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Female; Humans; Leukemia, Mast-Cell; Staurosporine | 2014 |
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
Topics: Adult; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Dasatinib; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles; Young Adult | 2014 |
Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.
Topics: Carbazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Furans; Humans; Indole Alkaloids; Polyploidy; Signal Transduction; Small Cell Lung Carcinoma; Staurosporine | 2015 |
Ets and GATA transcription factors play a critical role in PMA-mediated repression of the ckβ promoter via the protein kinase C signaling pathway.
Topics: Base Sequence; Cell Line, Tumor; Choline Kinase; CpG Islands; GATA Transcription Factors; Humans; Molecular Sequence Data; Mutation; Promoter Regions, Genetic; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Signal Transduction; Staurosporine; Tetradecanoylphorbol Acetate | 2014 |
Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Tretinoin | 2015 |
NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells.
Topics: Acute Disease; Animals; Blotting, Western; Cell Line; DNA Damage; fms-Like Tyrosine Kinase 3; Genomic Instability; HL-60 Cells; Humans; Hydrogen Peroxide; Leukemia, Myeloid; Mice; Microscopy, Confocal; Mutation; NADPH Oxidase 4; NADPH Oxidases; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Staurosporine; Tandem Repeat Sequences | 2015 |
Targeting a cell state common to triple-negative breast cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Female; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Protein Interaction Domains and Motifs; Protein-Tyrosine Kinases; Proteomics; Sequence Analysis, RNA; Signal Transduction; STAT3 Transcription Factor; Staurosporine; Syk Kinase; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics.
Topics: Calgranulin A; Cell Proliferation; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Docking Simulation; Molecular Targeted Therapy; Protein Conformation; Protein Kinase Inhibitors; Signal Transduction; Staurosporine | 2015 |
Screening of drugs to treat 8p11 myeloproliferative syndrome using patient-derived induced pluripotent stem cells with fusion gene CEP110-FGFR1.
Topics: Adolescent; Benzimidazoles; Cells, Cultured; Drug Evaluation, Preclinical; Hematopoiesis; Humans; Imatinib Mesylate; Imidazoles; Induced Pluripotent Stem Cells; Male; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyridazines; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Staurosporine; Translocation, Genetic | 2015 |
The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
Topics: Amino Acid Motifs; Catalysis; Crystallography, X-Ray; Cysteine; Disulfides; Dyrk Kinases; Humans; Models, Molecular; Phosphorylation; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Staurosporine; Substrate Specificity; Tyrosine | 2015 |
The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.
Topics: Animals; Antigens, CD; Azacitidine; Cadherins; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-kit; Staurosporine | 2015 |
PKC412 normalizes mutation-related keratin filament disruption and hepatic injury in mice by promoting keratin-myosin binding.
Topics: Animals; Intermediate Filaments; Keratins; Liver Diseases; Mice; Mice, Transgenic; Mutation; Myosins; Protein Binding; Staurosporine | 2015 |
Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.
Topics: Animals; Apoptosis; Aurora Kinase A; Aurora Kinase B; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Protein Kinase Inhibitors; Staurosporine; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression; Humans; Inhibitory Concentration 50; Isoquinolines; Leukemia, Myeloid, Acute; Mice, Inbred NOD; Mice, SCID; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-mdm2; Staurosporine; Tumor Burden; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.
Topics: Adult; Aged; Basophils; Cell Line, Tumor; Cell Survival; Female; Histamine Release; Humans; Male; Mast Cells; Mastocytosis; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Staurosporine | 2016 |
57th American Society of Hematology Annual Meeting.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Aurora Kinase A; Azepines; Chimera; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Hematology; Humans; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Peripheral; Multiple Myeloma; Pyrimidines; Societies, Medical; Staurosporine; T-Lymphocytes; United States | 2016 |
Midostaurin + Chemo Ups AML Survival.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Staurosporine; Survival Analysis; Treatment Outcome | 2016 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
Topics: Animals; Antineoplastic Agents; Culture Media; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Staurosporine | 2016 |
FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
Topics: Adolescent; Apoptosis; Biological Transport; Cell Line, Tumor; Child; Child, Preschool; Cytarabine; DNA Mutational Analysis; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Histone-Lysine N-Methyltransferase; Humans; Infant; Infant, Newborn; Male; Mutation; Myeloid-Lymphoid Leukemia Protein; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine | 2016 |
IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Brentuximab Vedotin; Cell Line, Tumor; Cytokines; Dog Diseases; Dogs; Down-Regulation; Drug Synergism; Female; Immunoconjugates; Interleukin-4; Ki-1 Antigen; Male; Mastocytosis; Piperidines; Pyridines; Staurosporine; Thiazoles | 2017 |
Activation of HIV-1 expression in latently infected CD4+ T cells by the small molecule PKC412.
Topics: CD4-Positive T-Lymphocytes; Drug Evaluation, Preclinical; HIV-1; Humans; Protein Kinase Inhibitors; Staurosporine; Virus Activation; Virus Latency | 2016 |
Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
Topics: Animals; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Xenograft Model Antitumor Assays | 2016 |
Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Cell Line, Tumor; Computational Biology; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Protein c-fli-1; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Somatomedin; RNA-Binding Protein EWS; Sarcoma, Ewing; Signal Transduction; Staurosporine; Xenograft Model Antitumor Assays | 2017 |
Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
Topics: Adult; Animals; Dogs; Female; Humans; Leukemia, Myeloid, Acute; Male; Mass Spectrometry; Middle Aged; Protein Kinase Inhibitors; Rats; Staurosporine; Young Adult | 2017 |
Midostaurin Gets FDA Nod for AML.
Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Staurosporine; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Female; Histone-Lysine N-Methyltransferase; Histones; Humans; K562 Cells; Lysine; Male; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Methylation; Middle Aged; Mutation; Prognosis; Proteasome Endopeptidase Complex; Staurosporine | 2018 |
Midostaurin in FLT3-mutated acute myeloid leukaemia.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Staurosporine; Treatment Outcome | 2017 |
A molecular roadmap for midostaurin in mastocytosis.
Topics: Humans; Mastocytosis; Staurosporine | 2017 |
New Approvals in Cancer Treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Approval; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Phenylurea Compounds; Pyridines; Staurosporine; United States; United States Food and Drug Administration | 2017 |
First new drug approval for AML in 15 years.
Topics: Aminoglycosides; Aminopyridines; Aniline Compounds; Antibodies, Monoclonal, Humanized; Drug Approval; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Staurosporine; Triazines | 2017 |
Midostaurin (Rydapt) for AML and advanced systemic mastocytosis.
Topics: Humans; Mastocytosis, Systemic; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2017 |
[Sensitivity of AML Cells with FLT3
Topics: Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Ketoconazole; Male; Midazolam; Middle Aged; Models, Biological; Rifampin; Staurosporine; Young Adult | 2018 |
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2017 |
First Approved Kinase Inhibitor for AML.
Topics: Antineoplastic Agents; Drug Approval; Humans; Leukemia, Myeloid, Acute; Staurosporine; United States; United States Food and Drug Administration | 2017 |
Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies
Topics: Antineoplastic Agents; Biological Products; Drug Approval; Hematologic Neoplasms; Humans; Protein Kinase Inhibitors; Staurosporine; Streptomyces | 2018 |
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Dasatinib; Dogs; Drug Resistance, Neoplasm; Drug Synergism; Female; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Mast-Cell; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Norbornanes; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; STAT5 Transcription Factor; Staurosporine; Tumor Suppressor Proteins; Young Adult | 2018 |
Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Nitriles; Protein Kinase Inhibitors; Pyridines; Staurosporine; Triazoles | 2019 |
In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
Topics: Benzamides; Benzimidazoles; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Indoles; Inhibitory Concentration 50; Microsomes, Liver; Phthalazines; Piperidines; Pyridines; Pyridones; Pyrimidinones; Quinolones; Staurosporine; Thiazoles | 2018 |
C6 ceramide motivates the anticancer sensibility induced by PKC412 in preclinical head and neck squamous cell carcinoma models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Ceramides; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liposomes; Male; Mice, SCID; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Squamous Cell Carcinoma of Head and Neck; Staurosporine; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
MDM2- and FLT3-inhibitors in the treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Nucleophosmin; Proto-Oncogene Proteins c-mdm2; Staurosporine | 2018 |
Mastocytosis: Moving the Field to Precision and Personalized Medicine.
Topics: Animals; Humans; Mast Cells; Mastocytosis; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quality of Life; Staurosporine; Tryptases; Urticaria Pigmentosa | 2018 |
Application of multi-state models in cancer clinical trials.
Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Statistics, Nonparametric; Staurosporine; Survival Analysis | 2018 |
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Staurosporine; United States; United States Food and Drug Administration | 2018 |
Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.
Topics: Animals; BALB 3T3 Cells; Cell Proliferation; Cells, Cultured; Fibroblasts; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Protein Kinase Inhibitors; Staurosporine | 2018 |
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells.
Topics: Aurora Kinase A; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Drug Discovery; Drug Synergism; Humans; Lung Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Proto-Oncogene Proteins; RNA Interference; Signal Transduction; Staurosporine | 2018 |
Midostaurin administration in two hemodialysis patients.
Topics: Aged; Antineoplastic Agents; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Renal Dialysis; Staurosporine | 2019 |
Neutropenic enterocolitis in patients with FLT3 mutated acute myeloid leukemia undergoing induction chemotherapy with midostaurin.
Topics: Adult; Aged; Enterocolitis, Neutropenic; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Staurosporine | 2019 |
Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia.
Topics: Antigens, Differentiation; Cytokines; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Signal Transduction; Staurosporine; T-Lymphocytes, Regulatory | 2018 |
The multikinase inhibitor EC-70124 synergistically increased the antitumor activity of doxorubicin in sarcomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carbazoles; Doxorubicin; Drug Synergism; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Sarcoma; Signal Transduction; Staurosporine; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Midostaurin potentiates rituximab antitumor activity in Burkitt's lymphoma by inducing apoptosis.
Topics: Animals; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, SCID; Neoplasm Proteins; Rituximab; Staurosporine; Xenograft Model Antitumor Assays | 2018 |
Closing in on targeted therapy for acute myeloid leukaemia.
Topics: Aniline Compounds; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazines; Staurosporine | 2019 |
The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Molecular Docking Simulation; Neoplasms; NIH 3T3 Cells; Protein Kinase Inhibitors; Staurosporine; Up-Regulation | 2019 |
Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.
Topics: CD4-Positive T-Lymphocytes; Cell Cycle Checkpoints; Cells, Cultured; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Macrophages; Phosphorylation; Protein Kinase Inhibitors; SAM Domain and HD Domain-Containing Protein 1; Staurosporine; Virus Activation; Virus Latency; Virus Replication | 2019 |
A Granular Approach to a Patient with Diarrhea and Flushing.
Topics: Antineoplastic Agents; Cell Degranulation; Colonic Neoplasms; Diarrhea; Flushing; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Mast Cells; Mastocytosis, Systemic; Middle Aged; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2019 |
Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post-haploidentical allogeneic stem cell transplant.
Topics: Humans; Male; Mastocytosis, Systemic; Middle Aged; Staurosporine; Transplantation, Homologous | 2019 |
Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Sialic Acid Binding Ig-like Lectin 3; Staurosporine | 2019 |
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Topics: Antineoplastic Agents; Cell Line; Drug Resistance, Neoplasm; Exons; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Staurosporine; Triazines | 2019 |
Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication.
Topics: Abdominal Pain; Gastritis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Staurosporine; Tomography, X-Ray Computed | 2020 |
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Mutant Proteins; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrazoles; Pyrroles; Sorafenib; Staurosporine; Triazines | 2019 |
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Remission Induction; Sorafenib; Staurosporine; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2019 |
Acute Myeloid Leukemia: A New Era of Therapies, a New Wave of Toxicities?
Topics: Acute Disease; Gastritis; Humans; Leukemia, Myeloid, Acute; Staurosporine | 2020 |
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Topics: Aniline Compounds; Animals; Apoptosis; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Staurosporine | 2019 |
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine | 2019 |
Real-Time NMR Spectroscopy for Studying Metabolism.
Topics: Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Glucose; Humans; Lactic Acid; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Magnetic Resonance Spectroscopy; Metabolome; Metabolomics; Staurosporine | 2020 |
Midostaurin: Nursing Perspectives on Managing Treatment and Adverse Events in Patients With FLT3 Mutation-Positive Acute Myeloid Leukemia and Advanced Systemic Mastocytosis.
Topics: Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Nausea; Staurosporine; United States; Vomiting | 2019 |
Treatment practice and outcomes in
Topics: Australia; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine; Tertiary Care Centers | 2020 |
Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
Topics: Adult; Aged; Cohort Studies; Comprehensive Health Care; Female; fms-Like Tyrosine Kinase 3; Health Care Costs; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Staurosporine; Treatment Outcome | 2019 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Midostaurin and cyclosporine drug interaction: A case report.
Topics: Aged; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Protein Kinase Inhibitors; Staurosporine | 2020 |
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antigens, CD34; Bone Marrow Cells; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Mice; Middle Aged; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Staurosporine | 2019 |
Monocytic Maturation Induced by FLT3 Inhibitor Therapy of Acute Myeloid Leukemia: Morphologic and Immunophenotypic Characteristics.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monocytes; Staurosporine; Young Adult | 2020 |
Pregnancy exposure to midostaurin in the first trimester.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Compassionate Use Trials; Cytarabine; Female; Fetal Growth Retardation; fms-Like Tyrosine Kinase 3; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Leukemia, Myeloid, Acute; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Protein Kinase Inhibitors; Recurrence; Staurosporine; Tandem Repeat Sequences | 2020 |
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
Topics: Animals; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid; Mice; Mutation; Proto-Oncogene Proteins c-cbl; Signal Transduction; Staurosporine; Syk Kinase | 2020 |
Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin.
Topics: Acute Kidney Injury; Administration, Intravenous; Antibodies, Antineutrophil Cytoplasmic; Biopsy; Combined Modality Therapy; Cyclophosphamide; Glomerulonephritis; Glucocorticoids; Hemorrhage; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Lung Diseases; Methylprednisolone; Middle Aged; Necrosis; Plasma Exchange; Protein Kinase Inhibitors; Renal Dialysis; Staurosporine; Treatment Outcome | 2020 |
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.
Topics: Cell Line, Tumor; Chemokine CCL5; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine; Up-Regulation | 2020 |
Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Staurosporine; Syk Kinase | 2020 |
Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; fms-Like Tyrosine Kinase 3; France; Health Expenditures; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Models, Econometric; Quality-Adjusted Life Years; Recurrence; Remission Induction; Staurosporine | 2020 |
A drug discovery platform to identify compounds that inhibit EGFR triple mutants.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; DNA Nucleotidyltransferases; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Genes, Reporter; High-Throughput Screening Assays; Humans; Luciferases; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Reproducibility of Results; Small Molecule Libraries; Staurosporine | 2020 |
Inhibition of human UDP-glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug-drug interactions.
Topics: Antineoplastic Agents; Drug Interactions; Glucuronosyltransferase; Humans; Isoenzymes; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recombinant Proteins; Staurosporine | 2020 |
Updated safety of midostaurin plus chemotherapy in newly diagnosed
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Radius; Staurosporine | 2020 |
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Frequency; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Staurosporine; Transplantation, Homologous; Treatment Outcome | 2021 |
Acute leukemias in 2020: state of the art.
Topics: Acute Disease; Aminopyridines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Congresses as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia; Pyridines; Recombinant Fusion Proteins; Staurosporine; Triazines | 2020 |
Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism.
Topics: Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Colorectal Neoplasms; Daunorubicin; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; HCT116 Cells; Humans; Leukemia, Myeloid, Acute; Staurosporine | 2021 |
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Nucleophosmin; Staurosporine | 2020 |
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; CRISPR-Cas Systems; Female; fms-Like Tyrosine Kinase 3; Gene Knockout Techniques; Genetic Therapy; Humans; Leukemia, Myeloid, Acute; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Staurosporine; Sulfonamides | 2020 |
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Janus Kinases; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2021 |
[Inhibitory Effect of PKC412 Against Human Acute Leukemia Cell Line HL-60 Cells].
Topics: Animals; Apoptosis; Cell Proliferation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Proto-Oncogene Proteins c-bcl-2; Staurosporine | 2021 |
Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
Topics: Biomarkers; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Leukemia; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Staurosporine | 2021 |
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A; Diarrhea; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Mycoses; Staurosporine; Triazoles | 2021 |
Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Sorafenib; Staurosporine | 2021 |
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Pyrones; Quinolines; rac1 GTP-Binding Protein; Staurosporine; Sulfonamides | 2021 |
Impurity profiling and stability-indicating method development and validation for the estimation of assay and degradation impurities of midostaurin in softgel capsules using HPLC and LC-MS.
Topics: Capsules; Chromatography, High Pressure Liquid; Drug Contamination; Limit of Detection; Linear Models; Mass Spectrometry; Reproducibility of Results; Staurosporine | 2021 |
Neutrophilic Eccrine Hidradenitis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hidradenitis; Humans; Leukemia, Monocytic, Acute; Staurosporine | 2021 |
The Protein Kinase Inhibitor Midostaurin Improves Functional Neurological Recovery and Attenuates Inflammatory Changes Following Traumatic Cervical Spinal Cord Injury.
Topics: Animals; Cervical Cord; Female; Inflammation; Neuroprotective Agents; Protein Kinase Inhibitors; Rats; Rats, Wistar; Recovery of Function; Spinal Cord Injuries; Staurosporine | 2021 |
Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Staurosporine; Sweet Syndrome; United States | 2021 |
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Lineage; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2022 |
Bullous Sweet syndrome in a patient with acute myeloid leukemia treated with midostaurin: Rapid response to acitretin and colchicine-A case report.
Topics: Acitretin; Colchicine; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine; Sweet Syndrome | 2021 |
FLT3-ITD transduces autonomous growth signals during its biosynthetic trafficking in acute myelogenous leukemia cells.
Topics: Benzothiazoles; Cell Membrane; Cell Proliferation; Endoplasmic Reticulum; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Golgi Apparatus; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mutation; Oncogenes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Staurosporine; Tandem Repeat Sequences; THP-1 Cells; Tumor Suppressor Proteins | 2021 |
Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience.
Topics: Humans; Mast Cells; Mastocytosis; Mastocytosis, Systemic; Retrospective Studies; Staurosporine | 2022 |
Midostaurin-induced lichenoid photoallergic reaction in a patient with systemic mastocytosis.
Topics: Humans; Lichenoid Eruptions; Mastocytosis, Systemic; Protein Kinase Inhibitors; Staurosporine | 2022 |
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
Topics: Aged; Female; Humans; Leukemia, Mast-Cell; Male; Mastocytosis; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Retrospective Studies; Staurosporine | 2022 |
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
Topics: Antifungal Agents; Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
ABCB1 as a potential beneficial target of midostaurin in acute myeloid leukemia.
Topics: Anthracyclines; ATP Binding Cassette Transporter, Subfamily B; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MicroRNAs; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Topics: Aniline Compounds; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Sorafenib; Staurosporine | 2022 |
Kinase Inhibition by PKC412 Prevents Epithelial Sheet Damage in Autosomal Dominant Epidermolysis Bullosa Simplex through Keratin and Cell Contact Stabilization.
Topics: Cytoskeletal Proteins; Cytoskeleton; Epidermolysis Bullosa Simplex; Humans; Keratin-14; Keratin-5; Keratins; Mutation; Staurosporine | 2022 |
Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
Topics: Animals; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Tretinoin | 2022 |
Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia.
Topics: Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Staurosporine | 2022 |
Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience.
Topics: Adult; Feasibility Studies; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Peripheral Blood Stem Cells; Protein Kinase Inhibitors; Staurosporine | 2023 |
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Topics: Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2023 |
Real-World Efficacy Outcomes of FLT3-ITD
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Staurosporine | 2023 |
Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin.
Topics: Humans; Mastocytosis; Mastocytosis, Systemic; Mutation; Staurosporine | 2023 |
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for
Topics: Czech Republic; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Staurosporine | 2023 |
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Staurosporine | 2023 |
A Functional Pipeline of Genome-Wide Association Data Leads to Midostaurin as a Repurposed Drug for Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Drug Repositioning; Genome-Wide Association Study; Mice; Staurosporine | 2023 |
Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level.
Topics: Combined Modality Therapy; Humans; Leukemia, Mast-Cell; Male; Mast Cells; Middle Aged; Staurosporine; Tumor Microenvironment | 2023 |